Patent Grant
12151071
The present technology generally relates to implantable medical devices and, in particular, to implantable interatrial systems and associated methods for selectively controlling blood flow between the right atrium and the left atrium of a heart.
Heart failure is a medical condition associated with the inability of the heart to effectively pump blood to the body. Heart failure affects millions of people worldwide, and may arise from multiple root causes, but is generally associated with myocardial stiffening, myocardial shape remodeling, and/or abnormal cardiovascular dynamics. Chronic heart failure is a progressive disease that worsens considerably over time. Initially, the body's autonomic nervous system adapts to heart failure by altering the sympathetic and parasympathetic balance. While these adaptations are helpful in the short-term, over a longer period of time they may serve to make the disease worse.
Heart failure (HF) is a medical term that includes both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). The prognosis with both HFpEF and HFrEF is poor; one-year mortality is 26% and 22%, respectively, according to one epidemiology study. In spite of the high prevalence of HFpEF, there remain limited options for HFpEF patients. Pharmacological therapies have been shown to impact mortality in HFrEF patients, but there are no similarly-effective evidence-based pharmacotherapies for treating HFpEF patients. Current practice is to manage and support patients while their health continues to decline.
A common symptom among heart failure patients is elevated left atrial pressure. In the past, clinicians have treated patients with elevated left atrial pressure by creating a shunt between the left and right atria using a blade or balloon septostomy. The shunt decompresses the left atrium (LA) by relieving pressure to the right atrium (RA) and systemic veins. Over time, however, the shunt typically will close or reduce in size. More recently, percutaneous interatrial shunt devices have been developed which have been shown to effectively reduce left atrial pressure. However, these percutaneous devices often have an annular passage with a fixed diameter which fails to account for a patient's changing physiology and condition. For this reason, existing percutaneous shunt devices may have a diminishing clinical effect after a period of time. Many existing percutaneous shunt devices typically are also only available in a single size that may work well for one patient but not another. Also, sometimes the amount of shunting created during the initial procedure is later determined to be less than optimal months later. Accordingly, there is a need for improved devices, systems, and methods for treating heart failure patients, particularly those with elevated left atrial pressure.
The present technology is directed to adjustable interatrial shunting systems that selectively control blood flow between the LA and the RA of a patient. For example, in many of the embodiments disclosed herein, the adjustable interatrial devices include a shunting element having an outer surface configured to engage native tissue and an inner surface defining a lumen that enables blood to flow from the LA to the RA when the device is deployed across the septal wall. In many embodiments, the systems include an actuation assembly that can adjust a geometry of the lumen and/or a geometry of a lumen orifice to control the flow of blood through the lumen. In many of the embodiments described herein, the actuation assembly includes one or more actuation elements composed of a shape-memory material and configured to undergo a material phase transformation when heated above a transition temperature that is greater than body temperature.
The terminology used in the description presented below is intended to be interpreted in its broadest reasonable manner, even though it is being used in conjunction with a detailed description of certain specific embodiments of the present technology. Certain terms may even be emphasized below; however, any terminology intended to be interpreted in any restricted manner will be overtly and specifically defined as such in this Detailed Description section. Additionally, the present technology can include other embodiments that are within the scope of the claims but are not described in detail with respect to
Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present technology. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features or characteristics may be combined in any suitable manner in one or more embodiments.
Reference throughout this specification to relative terms such as, for example, “about” and “approximately” are used herein to mean the stated value plus or minus 10%.
As used herein, in various embodiments, the terms “interatrial device,” “interatrial shunt device,” “IAD,” “IASD,” “interatrial shunt,” and “shunt” are used interchangeably and, in at least one configuration, refer to a shunting element that provides a blood flow between a first region (e.g., a LA of a heart) and a second region (e.g., a RA or coronary sinus of the heart) of a patient. Although described in terms of a shunt between the atria, namely the LA and the RA, one will appreciate that the technology may be applied equally to other medical devices. For example, the shunt may be positioned between other chambers and passages of the heart or other parts of the cardiovascular system. For example, any of the shunts described herein, including those referred to as “interatrial,” may be nevertheless used and/or modified to shunt between the LA and the coronary sinus, or between the right pulmonary vein and the superior vena cava. Moreover, while the disclosure herein primarily describes shunting blood from the LA to the RA, the present technology can be readily adapted to shunt blood from the RA to the LA to treat certain conditions, such as pulmonary hypertension. For example, mirror images of embodiments, or in some cases identical embodiments, used to shunt blood from the LA to the RA can be used to shunt blood from the RA to the LA in certain patients. In another example, the shunt may be used to facilitate flow between an organ and organ, organ and vessel, etc. The shunt may also be used for fluids other than blood. The technologies described herein may be used for an ophthalmology shunt to flow aqueous or fluids to treat gastrointestinal disorders. The technologies described herein may also be used for controlled delivery of other fluids such as saline, drugs, or pharmacological agents.
As used herein, the term “geometry” can include the size and/or the shape of an element. Accordingly, when the present disclosure describes a change in geometry, it can refer to a change in the size of an element (e.g., moving from a smaller circle to a larger circle), a change in the shape of an element (e.g., moving from a circle to an oval), and/or a change in the shape and size of an element (e.g., moving from a smaller circle to a larger oval). In various embodiments, “geometry” refers to the relative arrangements and/or positions of elements in the respective system.
As used herein, the term “manufactured geometry” can refer a preferred geometric configuration of a shape memory component. For example, the shape memory component generally assumes the manufactured geometry in the absence of mechanical stresses or other deformations. The manufactured geometry can include an “as cut” geometry, a heat set geometry, a shape set geometry, or the like.
The headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed present technology.
A. Interatrial Shunts for Treatment of Heart Failure
Heart failure can be classified into one of at least two categories based upon the ejection fraction a patient experiences: (1) HFpEF, historically referred to as diastolic heart failure or (2) HFrEF, historically referred to as systolic heart failure. One definition of HFrEF is a left ventricular ejection fraction lower than 35%-40%. Though related, the underlying pathophysiology and the treatment regimens for each heart failure classification may vary considerably. For example, while there are established pharmaceutical therapies that can help treat the symptoms of HFrEF, and at times slow or reverse the progression of the disease, there are limited available pharmaceutical therapies for HFpEF with only questionable efficacy.
In heart failure patients, abnormal function in the left ventricle (LV) leads to pressure build-up in the LA. This leads directly to higher pressures in the pulmonary venous system, which feeds the LA. Elevated pulmonary venous pressures push fluid out of capillaries and into the lungs. This fluid build-up leads to pulmonary congestion and many of the symptoms of heart failure, including shortness of breath and signs of exertion with even mild physical activity. Risk factors for HF include renal dysfunction, hypertension, hyperlipidemia, diabetes, smoking, obesity, old age, and obstructive sleep apnea. HF patients can have increased stiffness of the LV which causes a decrease in left ventricular relaxation during diastole resulting in increased pressure and inadequate filling of the ventricle. HF patients may also have an increased risk for atrial fibrillation and pulmonary hypertension, and typically have other comorbidities that can complicate treatment options.
Interatrial shunts have recently been proposed as a way to reduce elevated left atrial pressure, and this emerging class of cardiovascular therapeutic interventions has been demonstrated to have significant clinical promise.
One challenge with many conventional interatrial shunts is determining the most appropriate size and shape of the shunt lumen. A lumen that is too small may not adequately unload the LA and relieve symptoms; a lumen that is too large may overload the RA and right-heart more generally, creating new problems for the patient. Moreover, the relationship between pressure reduction and clinical outcomes and the degree of pressure reduction required for optimized outcomes is still not fully understood, in part because the pathophysiology for HFpEF (and to a lesser extent, HFrEF) is not completely understood. As such, clinicians are forced to take a best guess at selecting the appropriately sized shunt (based on limited clinical evidence) and generally cannot adjust the sizing over time. Worse, clinicians must select the size of the shunt based on general factors (e.g., the size of the patient's anatomical structures, the patient's hemodynamic measurements taken at one snapshot in time, etc.) and/or the design of available devices rather than the individual patient's health and anticipated response. With traditional devices, the clinician does not have the ability to adjust or titrate the therapy once the device is implanted, for example, in response to changing patient conditions such as progression of disease. By contrast, interatrial shunting systems configured in accordance with embodiments of the present technology allow a clinician to select the size—perioperatively or post-implant—based on the patient.
B. Shape Memory Actuation Assemblies
As provided above, the present technology is generally directed to interatrial shunting systems. Such systems include a shunting element implantable into a patient at or adjacent to a septal wall. In some embodiments, the shunting element includes a frame configured to interface with the septal wall, and a membrane coupled to the frame and defining a lumen. The shunting element (e.g., the lumen) can fluidly connect the LA and the RA of the patient to facilitate blood flow therebetween. In some embodiments, the shunting element includes and/or is operably coupled to an actuation assembly that is invasively and/or non-invasively adjustable to selectively control blood flow between the LA and the RA. In some embodiments, the systems can further include energy receiving components, energy storage components, and/or one or more sensors, among other things.
In some embodiments, an interatrial shunting system includes an actuation assembly having one or more actuation elements. As described in detail below, the actuation elements are configured to change a geometry or other characteristic of a lumen extending through the shunting element to alter the flow of fluid through the lumen. For example, in some embodiments the actuation elements can selectively change a size and/or shape of the lumen to alter the flow of fluid through the lumen. In particular, the actuation elements can be configured to selectively increase a diameter of the lumen (or a portion of the lumen) and/or selectively decrease a diameter of the lumen (or a portion of the lumen) in response to an input. Throughout the present disclosure, reference to adjusting a diameter (e.g., increasing a diameter, decreasing a diameter, etc.) can refer to adjusting a hydraulic or equivalent diameter of the lumen, adjusting a diameter at a particular location of the lumen, and/or adjusting a diameter along a length (e.g., a full length) of the lumen. In other embodiments, the actuation elements are configured to otherwise affect a shape or geometry of the lumen. In some embodiments, the actuation elements are configured to adjust a geometry (e.g., a cross-sectional area, a diameter, a dimension) of an orifice or aperture of the lumen (e.g., an inflow orifice or an outflow orifice positioned within or adjacent the LA or the RA, respectively). For example, the actuation elements can be configured to selectively increase a cross-sectional area of the outflow orifice in the RA and/or selectively decrease a cross-sectional area of an outflow orifice in the RA in response to an input. In some embodiments, the actuation elements can selectively change a geometry of both a lumen and a lumen orifice.
The actuation elements can therefore be coupled to the shunting element and/or can be included within the shunting element to drive the geometry change in the lumen and/or orifice. In some embodiments the actuation elements are part of the shunting element and at least partially define the lumen. For example, the actuation elements can be disposed within or otherwise coupled to a membrane that at least partially defines a lumen of the shunting element. In other embodiments, the actuation elements are spaced apart from but are operably coupled to the shunting element.
In some embodiments, at least a portion of the actuation elements can comprise a shape memory element. The shape memory portion can include a shape memory metal or alloy such as nitinol, a shape memory polymer, a pH-based shape memory material, or any other suitable material configured to move or otherwise adjust in response to an input. For example, the actuation elements can include one or more nitinol elements that are configured to change shape in response to applied heat that raises the nitinol elements' temperature above the material's transformation temperature. In such embodiments, the actuation elements can be selectively actuated by applying energy to heat the nitinol element(s). In some embodiments, the shape memory materials may extend around at least a portion of the lumen. In some embodiments, the shape memory materials may extend around at least a portion of a lumen orifice. In some embodiments, the shape memory materials may be separate from but operably coupled to the lumen and/or the lumen orifice.
Movement of an actuation element can be generated through externally-applied input and/or the use of a shape memory effect (e.g., as driven by a change in temperature). The shape memory effect enables deformations that have altered an element from its original or preferred shape-set geometric configuration (also referred to herein as “manufactured geometry” or “heat set geometry”) to be largely or entirely reversed during operation of the actuation elements. For example, sufficient heating can reverse deformations by producing a change in material state (e.g., phase change) in the actuator material, inducing a temporary elevated internal stress that promotes a shape change toward the original shape-set geometric configuration. For a shape memory alloy, the change in state can be from a martensitic phase (alternatively, R-phase) at the lower temperature to an austenitic phase (alternatively, R-phase) at the higher temperature. For a shape memory polymer, the change in state can be via a glass transition temperature or a melting temperature. The change in material state can recover deformation(s) of the material—for example, deformation with respect to its manufactured geometry—without any externally applied stress to the actuator element. That is, a deformation that is present in the material at a first temperature (e.g., body temperature) can be recovered and/or altered by raising the material to a second (e.g., higher) temperature. Upon cooling (and re-changing state, e.g., back to a martensitic phase), the actuator element may approximately retain its manufactured geometry. However, with the material in this relatively cooler-temperature condition it may require a lower force or stress to thermoelastically deform the material, and any subsequently applied external stress can cause the actuator element to once again deform away from the manufactured geometry.
The shape memory alloy actuation elements can be processed such that a transition temperature at which the change in state occurs (e.g., the austenite start temperature, the austenite final temperature, etc.) is above a threshold temperature (e.g., body temperature). For example, the transition temperature can be set to be about 40 deg. C., about 45 deg. C., about 50 deg. C., about 55 deg. C., about 60 deg. C., or another higher or lower temperature. In some embodiments, the actuator material is heated from body temperature to a temperature above the austenite start temperature (or alternatively above the R-phase start temperature) such that an upper plateau stress (e.g., “UPS_body temperature”) of the material in a first state (e.g., thermoelastic martensitic phase, or thermoelastic R-phase at body temperature) is lower than an upper plateau stress (e.g., “UPS_actuated temperature”) of the material in a heated state (e.g., superelastic state), which achieves partial or full free recovery. For example, the actuator material can be heated such that UPS_actuated temperature>UPS_body temperature. In some embodiments, the actuator material is heated from body temperature to a temperature above the austenite start temperature (or alternatively above the R-phase start temperature) such that an upper plateau stress of the material in a first state (e.g., thermoelastic martensite or thermoelastic R-phase at body temperature”) is lower than a lower plateau stress (e.g., “LPS”) of the material in a heated state (e.g., superelastic state), which achieves partial or full free recovery. For example, the actuator material can be constructed such that LPS_activated temperature>UPS_body temperature. In some embodiments, the actuator material is heated from body temperature to a temperature above the austenite start temperature (or alternatively above the R-phase start temperature) such that an upper plateau stress of the material in a first state (e.g., thermoelastic martensite or thermoelastic R-phase) is higher than a lower plateau stress of the material in a heated state, which achieves partial free recovery. For example, the actuator material can be constructed such that LPS_activated temperature<UPS_body temperature.
In some embodiments, the actuation assembly is formed by a coupling of at least two actuation elements (e.g., that have differing manufactured geometries) to form a composite actuation element (which can also be referred to as the “actuation assembly”). In some embodiments, at least one of the elements comprising the composite actuation element is a shape memory element. In some embodiments, both the elements comprising the composite actuation element are shape memory elements. In some embodiments, the coupling is performed with at least one actuation element in a thermoelastically deformable (e.g., thermoelastic martensitic or thermoelastic R-phase) state at the implantation temperature. In some embodiments, the coupling is performed with at least one actuation element(s) in a superelastic state. In some embodiments the flow control element comprises an expandable element or a contractile element whose deformation may be achieved via the application of a force (e.g., balloon expansion) at a lower temperature (e.g., body temperature) and/or via the application of a heat (e.g., electrical resistive heating) at a higher temperature (e.g., at a temperature at or above the austenite start or R-phase start temperature). In some embodiments, a shape memory component is constructed in a manner comprising a geometry (e.g., a cross-sectional area, a diameter, a length, a radius of curvature, or a circumference). In some embodiments, at least two actuation elements have geometric configurations (e.g., diameters) DA0 and DB0, where DA0>DB0. In some embodiments, the actuation assembly is formed of at least two actuation elements that have been constructed in substantially the same geometric configuration (e.g., DA0=DB0). The flow control element can be assembled such that, prior to or upon introduction into the patient (i.e., implantation), at least one of two or more coupled actuation elements are deformed with respect to their original geometric configuration (e.g., such that DA1≠DA0, and/or DB1≠DB0). In some embodiments, at least two coupled actuation elements can be deformed prior to or upon implantation such that a geometry (e.g. a diameter) of the first actuation element is smaller (e.g., compressed) with respect to its original configuration (e.g., DA1<DA0), and that a geometry (e.g., a diameter) of the second actuation element is larger (e.g., expanded) with respect to its original configuration (e.g., DB1>DB0). Thermoelastic deformation of the actuation elements to a desired configuration can occur with the shape memory components in a first (e.g., martensitic) material state. At a given temperature, the coupled and deformed actuation elements can (e.g., at equilibrium) form a composite geometry (e.g., cross-sectional area) that has a dimension that differs from either of the shape set configurations of the first and second actuation elements. For example, the composite geometry (e.g., diameter, DC0) of the flow control element can be between the shape set configurations of the first and second actuation elements (e.g., DA0>DC0>DB0).
The actuation assembly can be formed such that, in operation (e.g., during actuation of an actuation element), its composite geometry and/or dimension is altered (e.g., such that DC1≠DC0). The flow control element can cause a change in an overall dimension of a fluid path (e.g., lumen). For example, the overall dimension can comprise an overall cross-sectional area, a diameter, a length, a circumference, or another attribute. In an embodiment, the first and second actuation elements that are coupled to form a composite element are arranged such that a movement of the first actuation element (e.g., via thermoelastic martensitic transformation to achieve free recovery) is accompanied by (e.g., causes) a complementary full or partial movement of the second actuation element—e.g., by inducing thermoelastic recoverable deformation of a relatively malleable second actuation element while it is at least partially in a thermoelastic martensitic (or thermoelastic R-phase) material state. (For brevity herein, in various embodiments the term “relatively malleable” is used to describe a material state where a component requires a lower force or stress to deform it when compared to another component, or when compared to the same component in a different material state). The movement(s) can comprise a compression (e.g., contraction) or an expansion (e.g., opening) of the composite element. The movement can comprise a deflection or a deformation, which may be fully- or partially-recoverable. The complementary movement of the second actuation element can comprise movement that is (a) along a same axis, (b) about a same axis, or (c) along a same dimension (e.g., radially) as the primary movement of the first actuation element, or another movement. In some embodiments, actuation of the first actuation element from a compressed geometry toward a larger shape set configuration geometry expands the composite geometry via the coupling of the first actuation element with the second actuation element. In some embodiments, this expansion places the composite geometry at a size that is larger than its equilibrium, but smaller than that of the original configuration of the first actuation element (e.g., DA0>DC1>DC0). In some embodiments, actuation of the second actuation element from an expanded geometry toward a smaller original configuration geometry contracts (e.g., compresses) the composite geometry, via the coupling of the second actuation element with the first actuation element. In some embodiments, this compression places the composite geometry at a size that is smaller than its equilibrium, but larger than that of the original configuration of the second actuation element (e.g., DC0>DC1>DB0).
In a method of operation of an embodiment of the present technology, selective heating of the first actuation element of the flow control element causes it to actuate toward its original geometric configuration (e.g., from DA1 toward DA0). Actuation can be caused by raising a temperature of the first actuation element at least to a threshold transition temperature. The transition temperature can be a phase transition temperature (e.g., R-phase start temperature, austenite start temperature, R-phase finish temperature, or austenite finish temperature). Raising temperatures to or beyond the transition temperature can induce a change of the material from a first phase (e.g., martensite or R-phase) to a second phase (e.g., R-phase or austenitic). During actuation of the first actuation element, the second actuation element is generally not heated (e.g., remains at or near body temperature), and therefore remains in a first (e.g., martensitic or R-phase) material state. As such, the second actuation element may be relatively malleable in this material state, thereby allowing the elevated forces from partial or complete free recovery of the first actuation element to drive a change in shape and/or geometry of the coupled second element (e.g., a compressive or contracting movement). Due to the relatively malleable nature of the second actuation element in this material state, it may largely retain this induced shape and/or geometry change without substantial recovery (e.g., generally only linear elastic recovery).
Following the completion of a heating period of the first actuation element, the first actuation element cools and transforms to the lower-temperature phase (e.g., martensite or R-phase), in which it is relatively malleable. To reverse the induced change in the configuration of the composite flow control element (e.g., its geometry), the second actuation element can be heated to or beyond its transition temperature to induce a phase change (e.g., to R-phase or austenite) and, consequently, partial or full free recovery in geometry towards its original geometric configuration (e.g., from DB1 toward DB0). As the first actuation element is not selectively heated and relatively malleable during this time, the return of the second actuation element to its original geometric configuration causes the composite geometry of the flow control element to change (e.g., to reduce in size). In some embodiments, the geometry of flow control element can be repeatably toggled (e.g., between expanded and contracted) by repeating the foregoing operations. The heating of an actuation element can be accomplished via application of incident energy (e.g., via a laser, resistive heating, or inductive coupling). The source of the incident energy may be either internal (e.g., delivered via a catheter) or external to the patient (e.g., non-invasively delivered RF energy).
In some embodiments, the first actuation element can be thermally insulated and/or electrically isolated from the second actuation element. Further, in some embodiments, the first and second actuation elements can be thermally insulated and/or electrically isolated from tissue and blood adjacent the implant site.
Accordingly, the present technology provides actuation assemblies having two or more shape memory material actuation elements that are manufactured into different geometric configurations and coupled together. In additional embodiments, the geometric configurations may be similar, with two or more actuation elements working in an antagonistic or complementary fashion to manipulate a geometric feature of an actuation assembly. In some embodiments, the actuation elements may be manufactured with similar chemical composition and/or thermo-mechanical post-treatments, i.e., they may have similar phase transition temperature profiles. In further embodiments, an actuation assembly may contain two or more actuation elements that have been manufactured with differing chemical composition and/or thermo-mechanical post-treatments such that they do not share identical phase transition temperature profiles. In operation of such an embodiment, energy may be applied to an entire composite actuation assembly (e.g., comprised of two or more individual actuation elements) and not all individual actuation elements may similarly deform toward their original geometric configurations. For example, a first actuation element may have a first transformation temperature profile, and a second actuation element may have a second, higher transformation temperature profile. Heating the composite actuation assembly to a temperature above the first, but below the second, transformation temperature (e.g. R-phase start, austenite start, R-phase finish, or austenite finish temperature) will induce a more substantial thermoelastic recovery in the first actuation element than the second actuation element. This will create a first geometric alteration of an actuation assembly. Heating the composite actuation assembly to a temperature above both the first and second transformation temperatures (e.g., R-phase start, austenite start, R-phase finish, or austenite finish temperature) may induce a meaningful thermoelastic recovery and actuation in both actuation elements. This will create a second geometric alteration of an actuation assembly which may differ from the first geometric alteration.
In embodiments, the geometric changes of an actuation assembly may be toggled between a number of states in response to the actuation of one or more actuation elements. In embodiments, reversal of a geometry change (e.g., making a lumen larger after it had previously been made smaller) is accomplished by utilizing multiple shape memory actuation elements that are coupled to work in an antagonistic manner. In embodiments, other mechanisms (e.g., springs, ratchets, elastic materials such as silicone, etc.) may be additionally or alternatively be utilized in conjunction with actuation elements to provide complementary or counter forces to those actuation elements, thereby affecting a geometry change of an actuation assembly.
In embodiments, the actuation assembly may be thermoelastically expanded to a cross-sectional geometry that is larger than the largest actuation element in the composite structure. For example, one actuation element may have an initial diameter, DA0, and another actuation element may have an initial diameter, DB0, such that DA0>DB0. In such a composite system, the actuation of either actuation element drives the composite actuation assembly to a diameter within the range DB0-DA0 (inclusive). If, for example, a physician expands (e.g., via the use of a balloon) the actuation assembly to a diameter greater than DA0 to enable the crossing of a tool (e.g., during deployment of a transcatheter mitral valve), the lumen of the actuation assembly may later be thermoelastically recovered by actuating either actuation element (e.g., by the application of heat) to drive the recovery of the diameter of the actuation assembly to the original range DB0-DA0. In various embodiments, the actuation assembly is expanded to a diameter greater than DA0 to enable the crossing of a catheter, for example a diagnostic catheter or for a therapeutic. In embodiments, plastic deformation of either (or both) actuation elements may result from the expansion to a lumen greater than DA0. Consequently, the achievable actuatable lumen range may shift to DB1-DA1 where DB1>DB0 and DA1>DA0 accounting for the permanent plastic deformation.
C. Shunting Assemblies with Adjustable Flow Lumens
The present technology provides interatrial shunting assemblies with adjustable flow lumens. For example,
Referring first to
The geometry of the lumen 225 can be adjusted to change the flow of blood therethrough. In some embodiments, the diameter at a particular location of the lumen 225 is adjusted. For example, referring to
In other embodiments, the diameter of the lumen 225 is adjusted along its entire length. For example, referring to
In some embodiments, the geometry of the lumen 225 can be adjusted to increase the flow of blood therethrough. For example, the diameter of the lumen 225 can be increased. As shown in
As shown in
The present technology thus provides adjustable interatrial shunting systems that can adjust a geometry of a flow lumen and/or lumen orifice to change the flow of blood therethrough. In particular,
i. Stent-Like Actuation Assemblies
In some embodiments, at least one actuation element comprises an insulative element. For example, an actuation element can be coated with electrically- and/or thermally-insulative material. In some embodiments, the insulative element is flexible. The insulative element can comprise a polyimide (e.g., Kapton®), a synthetic polymer (e.g., polytetrafluoroethylene (PTFE) or expanded polytetrafluoroethylene (ePTFE)), thin ceramic coating (e.g., TiOx), or a urethane (e.g., ChronoFlex®), or another suitable material known to those skilled in the art. Polymeric insulative elements can have a dimension (e.g., coating thickness) that is, for example, about 50 microns, about 75 microns, about 100 microns, about 150 microns, about 300 microns, or about 1 millimeter. Ceramic insulative elements can have dimensions (e.g., layer thickness) that is, for example, about 5 nm, about 10 nm, about 100 nm, about 200 nm, about 300 nm, about 400 nm, or about 500 nm. The insulative element can have a dimension that is greater than, less than, or between any of the aforementioned dimensions.
The first and second actuation elements 405, 407 can comprise segments (404 and 409) that are configured to enable coupling to another actuation element or to another component of a device. In some embodiments, the portions for coupling comprise longitudinal struts. In embodiments, the segments for coupling can be maintained at a substantially fixed dimension (e.g., length) prior to and following construction of the actuation elements. In embodiments, two or more actuation elements may be coupled together by suture, adhesives/glue, rivets/crimps, welds, an enclosing sleeve, or via other methods. In some embodiments, at least one of the coupling portions (e.g., 404 or 409) comprises an insulative element. In some embodiments, the insulative element provides electrical isolation and/or thermal isolation between coupled actuation elements. As best seen in
One or more elements of the composite flow control element may be actuated to impart a geometry change of the composite structure. For example, actuation of the larger element may cause an increase and/or expansion of a geometric characteristic of the composite element such that it attains a new cross-sectional diameter DN1, where DN1>DC. Conversely, actuation of the smaller element may cause a decrease/contraction of a geometric characteristic of the composite element such that it attains a new cross-sectional diameter DN2, where DN2<DC.
To create an actuation assembly from the first and second actuation elements 505, 510, additional coupling steps may be implemented. For example, during a secondary coupling step, the flattened configuration of the stent structure (i.e., as shown in
In some embodiments, a third coupling operation may be undertaken to form the composite actuation assembly that includes both the first and second actuation elements 505, 510. In some embodiments, this operation involves using a flexible connection (e.g., an elastic polymer, a stretchable/flexible material, etc.) to couple the bent arms 502 and 507 of the first and second actuation elements 505, 510. For example, a flexible suture material can be utilized to connect the eyelet opening 518 on the first actuation element 505 with its assembled partner eyelet opening 519 on the second actuation element 510. Upon completion of this third coupling operation, the bend angle of arms 502 and 507 may each change and reach an equilibrium angular position. As with other coupling operations described herein, in embodiments the coupling may be performed in a way that maintains and/or establishes electrical and/or thermal isolation between the first and second actuation elements 505, 510. Following or prior to this third coupling operation, a membrane material (not shown) may be interfaced with the composite structure so as to provide an enclosed channel (e.g., an enclosed lumen) through which fluid may pass through the flow control element.
In an example method of use, following the third coupling operation described above, the composite actuation assembly comprised of the first and second actuation elements 505, 510 (e.g., which can also be referred to as “a flow control element”) can be (with or without integration into an interatrial shunting system) compressed into a delivery system (e.g., a catheter delivery system) and delivered to a body of a patient. In embodiments, once the composite actuation assembly is positioned in the desired location, it may be deployed and manually expanded to a neutral position (e.g., expanded using a catheter balloon expansion). In embodiments, the composite actuation assembly is in a material state (e.g., at least partially in a martensitic phase) where it is relatively malleable such that it is deformable from a delivery configuration to a neutral configuration. In embodiments, the composite actuation assembly is manufactured such that both at a first temperature (e.g., a room temperature) and at a second temperature higher than the first temperature (e.g., a body temperature), at least a portion of the composite actuation assembly remains in a material phase where it is relatively malleable and deformable (e.g., a nitinol alloy remains at least partially in a martensitic or R-phase).
As illustrated in
The functionality of the example embodiment shown in
In additional embodiments similar to those shown in
ii. Actuation Assemblies Having Elongated Actuation Elements
In addition to the stent-like actuation elements described with respect to
For example,
The system 800 includes a plurality of first actuation elements 806 (only one is shown in
Referring now to
The first actuation elements 806 and the second actuation elements 808 can be composed of a shape memory material, such as a shape memory alloy (e.g., nitinol). Accordingly, the first and second actuation elements 806, 808 can be transitionable between a first material state (e.g., a martensitic state, a R-phase, etc.) and a second state (e.g., a shape memory state, an austenitic state, etc.). In the first state, the first actuation elements 806 and the second actuation elements 808 may be deformable (e.g., plastic, malleable, compressible, expandable, etc.). In the second state, the first and second actuation elements 806, 808 may have a preference toward a specific manufactured geometry (e.g., shape, length, and/or or dimension). The first and second actuation elements 806, 808 can be transitioned between the first state and the second state by applying energy to the spindles to heat the spindles above a transition temperature. In some embodiments, the transition temperature for both the first actuation elements 806 and the second actuation elements 808 is above an average body temperature. Accordingly, both the first actuation elements 806 and the second actuation elements 808 are manufactured such that they are in the deformable first material state when the system 800 is implanted in the body.
If the actuation elements (e.g., the first actuation elements 806) are deformed while in the first material state, heating the actuation elements (e.g., the first actuation elements 806) above their transition temperature causes the actuation element to transition to the second material state and therefore transition from the deformed shape toward its manufactured geometry. Heat can be applied to the actuation elements via RF heating, resistive heating, or the like. In some embodiments, the first actuation elements 806 can be selectively heated independently of the second actuation elements 808, and the second actuation elements 808 can be selectively heated independently of the first actuation elements 806 (e.g., the first and second actuation elements are thermally and/or electrically isolated). For example, in some embodiments, the first actuation elements 806 are on a first electrical circuit for selectively and resistively heating the first actuation elements 806 and the second actuation elements 808 are on a second electrical circuit for selectively and resistively heating the second actuation elements 808. As described in detail below, selectively heating the first actuation elements 806 reduces a diameter of the lumen 802 and selectively heating the second actuation elements 808 increases a diameter of the lumen 802.
To drive actuation of the system 800, the first actuation elements 806 and the second actuation elements 808 generally are manufactured to have different manufactured geometries. Referring now to
Referring again to
The system 800 can be returned to the first configuration shown in
In some embodiments, the outer surface 912, the inner surface 914, the proximal surface 916a, and the distal surface 916b of the shunting element 910 define a generally toroidal shaped chamber 950. The chamber 950 can be fluidly isolated from the interior of the lumen 930. The chamber 950 can also be fluidly isolated from the environment surrounding the system 900 via the material encasing the shunting element 910. Accordingly, in some embodiments, the system 900 is configured to prevent blood from flowing into the chamber 950. In some embodiments, the chamber 950 can contain a compressible and/or displaceable liquid, gas, and/or gel. Accordingly, as the diameter of the lumen 930 is adjusted (as described below), the liquid or gas can be compressed, expanded, and/or displaced. In other embodiments, the shunting element 910 is substantially solid throughout its cross-section such that there is no chamber 950. In such embodiments, the shunting element 910 comprises an at least partially compressible and expandable material to conform to changes in the diameter of the lumen 930. The anchoring elements 920 are configured to secure the system 900 in a desired position within the heart. For example, as illustrated, the anchoring elements 920 can secure the system 900 to native heart tissue such as a septal wall S. In some embodiments, the anchoring elements 920 can include right atrium anchors and/or left atrium anchors. The anchoring elements 920 can extend from and/or be integral with one or more aspects of the shunting element 910.
The actuation assembly 940 is configured to selectively adjust a diameter of the lumen 930 to control the flow of blood therethrough. In the illustrated embodiment, the actuation assembly 940 comprises a first actuation element 942 and a second actuation element 944. The first actuation element 942 and the second actuation element 944 wrap around the lumen 930 defined by the inner surface 914. For example, the first actuation element 942 and the second actuation element 944 have a generally helical configuration, with the lumen 930 disposed within the center of the helix. The first actuation element 942 and the second actuation element 944 can be embedded within a membrane defining the lumen and/or otherwise coupled to the inner surface 914 to drive radially movement of the inner surface 914. For example, in some embodiments, the inner surface 914 has a thickness, and the first actuation element 942 and the second actuation element 944 are embedded within the thickness of the inner surface 914. In some embodiments, the system 900 includes one or more fluidly, thermally, and/or electrically isolated channels 946 extending around the inner lumen 930 in a generally helical orientation. The first actuation element 942 and the second actuation element 944 can be housed within the channels 946. The channels 946 can be positioned within the chamber 950, can be embedded within a thickness of the of inner surface 914, and/or can be positioned within the lumen 930 itself. In some embodiments, the system 900 can include a first channel for housing the first actuation element 942 and a second channel for housing the second actuation element 944. In other embodiments, a single channel houses both the first actuation element 942 and the second actuation element 944. The one or more channels 946 are sized and shaped to protect the actuation elements from the environment external to the system 900, and may also electrically and/or thermally isolate the first actuation element 942 from the second actuation element 944.
The first actuation element 942 includes a proximal end region 942a secured to the system 900 and a distal end region 942b secured to the system 900. Likewise, the second actuation element 944 includes a proximal end region 944a secured to the system 900 and a distal end region 944b secured to the system 900. The illustrated embodiment depicts the proximal end regions 942a, 944a secured to a portion of the anchoring element 920 and the distal end regions 942b, 944b, secured to the shunting element 910. However, one skilled in the art will appreciate that the first actuation element 942 and the second actuation element 944 can be secured to any number of structures of system 900 without deviating from the scope of the present technology.
The first actuation element 942 and the second actuation element 944 can be composed of any material suitable to dynamically adjust a diameter of the lumen 330. For example, in some embodiments, the first actuation element 942 and the second actuation element 944 can be composed of a shape-memory material, such as a shape memory alloy (e.g., nitinol). Accordingly, the first and second actuation elements 806, 808 can be transitionable between a first material state (e.g., a martensitic state, a R-phase, etc.) and a second material state (e.g., a shape memory state, an austenitic state, etc.). In the first state, the first actuation elements 806 and the second actuation elements 808 may be deformable (e.g., plastic, malleable, compressible, expandable, etc.). In the second state, the first and second actuation elements 806, 808 may have a preference toward a specific manufactured geometry (e.g., shape, length, and/or or dimension). The first and second actuation elements 942, 944 can be transitioned between the first state and the second state by applying energy to the first and/or second actuation elements 942, 944 to heat (e.g., resistively heat) the first and/or second actuation elements 942, 944 above a transition temperature. In some embodiments, the transition temperature for both the first actuation element 942 and the second actuation element 944 is above an average body temperature. Accordingly, both the first actuation element 942 and the second actuation element 944 are manufactured such that they are in the deformable first state when the system 900 is implanted in the body until they are heated (e.g., actuated).
At least one of the first actuation element 942 and the second actuation element 944 can be at least partially deformed relative to its manufactured geometry when implanted. For example, if the first actuation element 942 is deformed relative to its manufactured geometry, actuating the first actuation element 942 (e.g., by heating it above its transition temperature) causes the first actuation element 942 to move toward its manufactured geometry, which can tighten the first actuation element 942 and cause the lumen 930 to decrease in diameter. If the second actuation element 944 is deformed relative to its manufactured geometry, actuating the second actuation element 944 (e.g., by heating it above its transition temperature) can loosen the second actuation element 944 and cause the lumen 930 to increase in diameter.
Referring to
In some embodiments, the first and second actuation elements 1042, 1044 can be composed of a shape memory material and operate in a manner substantially similar to that described above with respect to the system 900. In other embodiments, the system 1000 can include an additional actuator (e.g., a motor, such as an electromagnetic motor, a mechanical motor, a MEMS motors, a piezoelectric based motor, or the like; not shown) configured to selectively adjust the first actuation element 1042 and the second actuation element 1044. For example, the actuator can adjust the first actuation element 1042 by pulling the proximal end segment 1042a and/or the distal end segment 1042b of the first actuation element 1042, thereby tightening the first actuation element 1042 around the inner surface 1014. Tightening the first actuation element 1042 around the inner surface causes the diameter of the lumen 1030 to decrease. For example, referring to
Actuating the second actuation element 1044 can have the opposite effect of actuation of the first actuation element 1042. For example, actuating the second actuation element 1044 via the actuator and/or via its shape memory properties can increase the diameter of the lumen 1030. More specifically, actuating the second actuation element 1044 causes the second actuation element 1044 to loosen around the inner surface, allowing the inner surface 1014 to expand radially outward. This increases the diameter of the lumen 1030. The second actuation element 1044 can be configured to retain its shape following actuation, thereby retaining the desired diameter until the actuator is further activated. Accordingly, the first actuation element 1042 can be actuated to decrease the diameter of the lumen 1030 and the second actuation element 1044 can be actuated to increase the diameter of the lumen 1030. By having opposite effects, a user can selectively adjust either the first actuation element 1042 or the second actuation element 1044 to achieve a desired lumen diameter.
In some embodiments, the first actuation element 1042 can be individually tightened and/or loosened via the actuator and/or the shape memory effect, and the second actuation element 1044 can be individually tightened and/or loosened via the actuator and/or the shape memory effect. In such embodiments, a single actuation element (e.g., the first actuation element 1042) can be sufficient to both increase and decrease the diameter of the lumen 1030. Additional actuation elements can still be included, however, to further increase the control and operability of the system 1000. Accordingly, some embodiments of the system 1000 include one, two, three, four, five, six, seven, and/or eight or more actuation elements.
The system 1100 can include a plurality of actuation elements 1142. For example, the system can include a first actuation element 1142a, a second actuation element 1142b, a third actuation element 1142c, a fourth actuation element 1142d, a fifth actuation element 1142e, a sixth actuation element 1142f, and a seventh actuation element 1142g. Other embodiments can include additional or fewer actuation elements 1142. The actuation elements 1142 wrap around the lumen 1130 (e.g., within the membrane defining the inner surface 1114) and are secured to the shunting element 1110. In some embodiments, individual actuation elements (e.g., the first actuation element 1142a) wrap around the lumen a single time. In other embodiments, individual actuation elements (e.g., first actuation element 1142a) wrap around the lumen more than once. For example, each individual actuation element could be wrapped around both the LA side and the RA side of lumen 1130 such that the diameter of the lumen 1130 is adjusted along a substantial length of the lumen 1130. As described above with respect to
Each of the actuation elements 1142a-g can be individually actuated. More specifically, each of the actuation elements 1142a-g can be individually actuated to transition from a passive configuration to an active configuration. When an individual actuation element (e.g., actuation element 1142a) is in the passive configuration, it does not dictate the diameter of the lumen 1130. When the individual actuation element (e.g., actuation element 1142a) is actuated and transitions to the active configuration, it adjusts the diameter of the lumen 1130 to a corresponding predetermined diameter. Accordingly, each of the actuation elements 1142a-g can be configured to selectively adjust the diameter of the lumen 1130 to a specific predetermined diameter. For example, actuating actuation element 1142a can adjust the diameter of lumen 1130 to about 12 mm, actuating actuation element 1142b can adjust the diameter of lumen 1130 to about 5 mm, actuating actuation element 1142c can adjust the diameter of lumen 1130 to about 6 mm, actuating actuation element 1142d can adjust the diameter of lumen 1130 to about 7 mm, actuating actuation element 1145e can adjust the diameter of lumen 1130 to about 8 mm, actuating actuation element 1145f can adjust the diameter of lumen 1130 to about 9 mm, and actuating actuation element 1145g can adjust the diameter of lumen 1130 to about 10 mm. Accordingly, specific actuation elements can be targeted to adjust the lumen 1130 to a desired diameter. Following actuation, individual actuation elements can be configured to remain in their active configuration, thereby retaining the corresponding lumen diameter until another individual actuation element is actuated.
In some embodiments, the actuation elements 1142 can be composed of shape-memory material, such as a shape memory alloy (e.g., nitinol). Accordingly, the actuation elements 1142 can be transitionable between a first material state (e.g., a martensitic state, a R-phase, etc.) and a second material state (e.g., a shape memory state, an austenitic state, etc.). In the first state, the actuation elements 1142 may be deformable (e.g., plastic, malleable, compressible, expandable, etc.). In the second state, the actuation elements 1142 may have a preference toward a specific manufactured geometry (e.g., shape, length, and/or or dimension). The actuation elements 1142 can be transitioned between the first state and the second state by applying energy to the actuation elements 1142 to heat (e.g., resistively heat) the actuation elements 1142 above a transition temperature. In some embodiments, the first material state corresponds to the passive configuration described previously and the second material state corresponds to the active configuration described previously. Therefore, in some embodiments the diameter of the lumen 1130 can be adjusted by heating an individual actuation element corresponding to a desired lumen diameter above its transition temperature, thereby transitioning the actuation element from the passive configuration to the active configuration.
In some embodiments, the actuation elements 1202-1204 are coupled mechanically. In some embodiments, the actuation elements 1202-1204 are thermoelastically manipulated (e.g., deformed) at least partially away from their original geometric configurations (e.g., manufactured geometries) prior to being coupled mechanically. In some embodiments, the actuation elements 1202-1204 are coupled in a manner such that they are nested serially (e.g., with the peaks and valleys of the sinusoid patterns aligning). The actuation elements 1202-1204 may be coupled using sutures, adhesives/glue, rivets/crimps, welds, etc., and/or may be coupled in part using the mechanical constraints/forces applied by the membrane 1201. In some embodiments, the actuation assembly 1220 may include insulative elements 1205 which may have a similar shape, pattern, and/or geometric configuration as one or more of the actuation elements 1202-1204. In some embodiments, the insulative elements 1205 are serially nested between the actuation elements 1202-1204. Additionally or alternatively, the insulative elements 1205 can be located at the ends of the composite element stack (i.e., at the front and back ends of the stack of serially nested elements, as shown in
To adjust a geometric property (e.g., the shape, diameter, etc.) of the actuation assembly 1220, energy is applied to one or more of the actuation elements 1202-1204 to raise the temperature of the element(s) above the phase transition temperature of the material (e.g., above the R-phase start, austenitic start, R-phase finish, or austenitic finish temperature). The actuated element(s) will undergo a thermoelastic recovery resulting in a shape and/or size change towards its original geometric configuration (e.g., its manufactured geometry). The remaining elements in the composite structure (to which no direct energy and, therefore, no substantial heat, is applied) will remain relatively malleable, and therefore deform in a manner complementary to the movement to the actuated element(s) (e.g., in response to force applied by the coupled actuated elements). By selectively applying energy to various actuation elements 1202-1204 or to various combinations of actuation elements, the actuation assembly 1220 may change geometric configuration (e.g., change shape, expand in cross-sectional area, decrease in cross-sectional area) in a manner that would impact the flow of a fluid therethrough. In embodiments, the actuation assembly 1220 may serve as the lumen for an interatrial shunting system. In other embodiments, the actuation assembly 1220 may integrate with or interface with a lumen of an interatrial shunting system (e.g., the membrane 1201 can be placed around a membrane of the shunting system that defines the shunt lumen.
In some embodiments, the plurality of actuator elements can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more discrete actuation elements. In some embodiments, the possible granularity of a geometry change of the actuation assembly 1220 can be increased by having an increased number of actuation elements. In some embodiments, geometry changes of the actuation assembly 1220 may be achieved via a partial transition of a selected actuation element from an initial state to a second state that is between the initial state and the original geometric configuration of the element. For example, pulses of energy may be delivered to heat the selected actuation element to a temperature that is between the austenite start temperature and the austenite finish temperature of the material (or alternatively between the R-phase start temperature and R-phase finish temperature). Alternatively or additionally, pulses of energy may be delivered to heat only a portion of the actuation element, leaving the rest of the actuation element at a temperature that does not induce a thermoelastic recovery. This may be accomplished, for example, by heating one or more attachments to an element (e.g., heating an element locally) instead of heating the element directly (e.g., global heating of an element).
The present technology also provides interatrial shunting systems having actuation elements that do not directly interface with the shunt lumen. For example, unlike the embodiments described with respect to
The shunting element 1401 can include a frame 1410 having an outer surface configured to engage native tissue, such as the septal wall S. In some embodiments, the frame 1410 can define a chamber 1414 that can encase a gel, fluid, foam, gas, or other substance that is compressible and/or displaceable. For example, in some embodiments, the substance can compress and/or expand in response to shape changes of the lumen 1405, described in greater detail below. In other embodiments, the substance can be displaced and/or return to its original location in response to shape changes of the lumen 1405. The shunting element 1401 further includes RA anchors 1424 and LA anchors 1426 configured to secure the device to the septal wall when implanted in a patient.
The shunting element 1401 can further include a membrane 1406 at least partially defining the lumen 1405. The membrane 1406 can define a portion of the chamber 1414, or can be coupled to a portion of the frame 1410 defining the chamber 1414. The membrane 1406 can be composed of any semi-flexible and biocompatible material, such as PTFE, ePTFE, silicone, nylon, polyethylene terephthalate (PET), polyether block amide (pebax), polyurethane, blends or combinations of these materials, or other suitable materials. In some embodiments, a plurality of spindles 1408 are disposed within or otherwise coupled to the membrane 1406. The spindles 1408 can extend at least partially between the first end flow aperture 1402 and the second end flow aperture 1404 and define a shape of the lumen 1405. In some embodiments, and as described in more detail below, the spindles 1408 can be bendable and configured to adjust a diameter of the lumen 1405, thereby controlling the amount of blood flowing through the lumen 1405. In some embodiments, the spindles 1408 are nitinol spindles and can be encased in a thin polymer, such as ePTFE. In some embodiments, the spindles 1408 are hollow and thin to facilitate bending.
The system 1400 can further include a first end element 1416 adjacent the first end flow aperture 1402 and a second end element 1418 adjacent the second end flow aperture 1404. The first end element 1416 can be generally circular or oval-shaped to avoid blocking blood flow through the lumen 1405. The spindles 1408 can extend between and be connected to the first end element 1416 and the second end element 1418. The system 1400 can further include an anchoring element 1420 positioned adjacent the first end element 1416. As one skilled in the art will appreciate from the disclosure herein, the anchoring element 1420 can be positioned adjacent the second end element 1418 and operate in a substantially similar manner. Accordingly, while the below description describes the system 1400 with the anchoring element 1420 positioned adjacent the first end element 1416, the present technology also includes “mirror image” embodiments in which the anchoring element 1420 is positioned adjacent the second end element 1418.
In the illustrated embodiment, the anchoring element 1420 and the second end element 1418 can be secured to a portion of the system 1400 fixedly secured to the septal wall (e.g., the outer surface 1412) and/or can be directly secured to the septal wall. Securing the anchoring element 1420 and the second end element 1418 to the system 1400 or the septal wall prevents the anchoring element 1420 and the second end element 1418 from moving during adjustment of the lumen diameter, as described below. The anchoring element 1420 can be coupled to the first end element 1416 via one or more actuation elements 1422. The actuation elements 1422 can be springs, coils, or other elements configured to adjust a distance between the anchoring element 1420 and the first end element 1416.
The first end element 1416 is moveable with respect to the anchor element 1420. For example, the first end element 1416 can move toward the anchoring element 1420, thereby bending the spindles 1408 inward (e.g., toward a central longitudinal axis of the lumen 1405) and decreasing an inner diameter of the lumen (e.g., moving from the configuration depicted in
Various embodiments of the system 1400 provide different mechanisms to adjust the distance between the anchoring element 1420 and the first end element 1416. For example, in some embodiments, the actuation elements 1422 can be composed of shape-memory material, such as a shape memory alloy (e.g., nitinol). Accordingly, the actuation elements 1422 can be transitionable between a first material state (e.g., a martensitic state, a R-phase, etc.) and a second material state (e.g., a shape memory state, an austenitic state, etc.). In the first state, the actuation elements 1422 may be deformable (e.g., plastic, malleable, compressible, expandable, etc.). In the second state, the actuation elements 1422 may have a preference toward a specific manufactured geometry (e.g., shape, length, and/or or dimension). The actuation elements 1422 can be transitioned between the first state and the second state by applying energy to the actuation elements 1422 to heat (e.g., resistively heat) the actuation elements 1422 above a transition temperature.
The actuation elements 1422 can be used to drive movement of the first end element 1416 toward or away from the anchor element 1420, thereby adjusting a diameter of the lumen 1405. For example, as shown in
In some embodiments, the actuation elements 1422 may operate without relying on shape memory characteristics. For example, in other embodiments, the actuation elements 1422 are springs having a first tension (e.g., spring constant). The first tension can be adjusted to a second tension to dictate how tightly the first end element 1416 is pulled toward the anchoring element 1420. For example, as the tension in the spring decreases, the distance between the anchoring element 1420 and the first end element 1416 increases, thereby increasing the inner diameter of the lumen 1405. As the tension in the spring increases, the distance between the anchoring element 1420 and the first end element 1416 decreases, thereby decreasing the inner diameter of the lumen 1405. In some embodiments, the spring tension can be adjusted via a magnet external to the patient. In other embodiments, the spring tension can be mechanically adjusted using an adjustment tool delivered via a catheter.
In another embodiment, the actuation elements 1422 are coils. Applying energy to the coils can adjust a length of the coils. For example, applying radiofrequency (“RF”) energy can selectively adjust the length of the coil, thereby (a) adjusting a distance between the anchoring element 1420 and the first end element 1416 and (b) adjusting the inner dimeter of the lumen 1405. In some embodiments, the RF energy can be applied externally from the patient to minimize the invasiveness of the adjustment procedure. In some embodiments, the RF energy is delivered at a low frequency to reduce signal attenuation and/or to reduce tissue heating. Low frequency signals include signals having frequencies between about 20 kHz and 300 kHz. However, one skilled in the art will appreciate that other frequencies, such as those less than 20 kHz or greater than 300 kHz, may be used in certain embodiments of the present technology. In some embodiments, the received RF energy may comprise about 10-30 watts. Due to scattering attenuation, however, the device may receive less power than transmitted. Accordingly, the device can be configured to operate with less power than transmitted, such as one watt.
In another embodiment, the system 1400 can include a mechanical adjustment element (e.g., a screw located on the first end element 1416 or the anchoring element 1420). In such embodiments, the system 1400 can be adjusted using an adjustment tool delivered to the system 1400 via a catheter. In another embodiment, the system 1400 can be adjusted using a balloon or other expandable element. For example, a balloon can be delivered into the lumen via a catheter. Inflating the balloon can apply a force that causes the spindles 1408 to bend outward away from the central longitudinal axis of the lumen 1405, thereby increasing the inner diameter of the lumen 1405. The spindles 1408 can comprise a relatively malleable material such that, following deflation and removal of the balloon, the lumen 1405 maintains the set inner diameter.
The system includes an actuation assembly 1620 extending from the frame 1610. The actuation assembly can include one or more rails 1628 and one or more actuation elements 1622. The membrane 1606 can be slidably coupled to the one or more rails 16281724 such that the first end flow aperture 1602 can move along the rails in a direction parallel to the longitudinal axis of the lumen 1605. The one or more actuation elements 1622 can be composed of shape-memory material, such as a shape memory alloy (e.g., nitinol). Accordingly, the actuation elements 1622 can be transitionable between a first material state (e.g., a martensitic state, a R-phase, etc.) and a second material state (e.g., a shape memory state, an austenitic state, etc.). In the first state, the actuation elements 1622 may be deformable (e.g., plastic, malleable, compressible, expandable, etc.). In the second state, the actuation elements 1622 may have a preference toward a specific manufactured geometry (e.g., shape, length, and/or or dimension). The actuation elements 1622 can be transitioned between the first state and the second state by applying energy to the actuation elements 1622 to heat (e.g., resistively heat) the actuation elements 1622 above a transition temperature.
In the illustrated embodiment, the actuation assembly 1620 includes a first actuation element 1622a and a second actuation element 1622b. The first actuation element 1622a extends from a proximal end 1620a of the actuation assembly 1620 and is coupled to a portion of the lumen 1605 at or adjacent the first end flow aperture 1602. The second actuation element 1622b extends from a distal end 1620b of the actuation assembly 1620 and is coupled to a portion of the lumen 1605 at or adjacent the first end flow aperture 1602. At least one of the first actuation element 1622a and the second actuation element 1622b is deformed relative to its manufactured geometry. For example,
The plate 1702 is configured to reside on a first side (e.g., a RA side) of the septal wall. In some embodiments, the system 1700 may have (e.g., additional) anchors configured to secure the system 1700 to the septal wall. For example,
Returning to
The actuation assembly 1720 includes a rim 1725 having a spine portion 1725a with a first anchor element 1721a and a second anchor element 1721b extending from and generally perpendicular to opposing end portions of the spine portion 1725a. The second anchor element 1721b can extend generally towards the shunting element 1710 to define a shunting element anchor 1726. In some embodiments, a portion of the shunting element anchor 1726 may engage an exterior surface portion of the shunting element 1710. Some or all of the rim 1725 can be secured to the plate 1702 and/or the septal wall. Accordingly, the rim 1725 is configured to remain static as the actuation assembly 1720 is actuated to adjust the size and/or shape of the lumen 1712, as described in greater detail below.
The actuation assembly 1720 further includes a moveable element 1723, a first actuation element 1722a extending between the first anchor element 1721a and the moveable element 1723, and a second actuation element 1722b extending between the second anchor element 1721b and the moveable element 1723. In the illustrated embodiment, the first actuation element 1722a is in a compressed state and the second actuation element 1722b is in a partially expanded state. However, as will be described in greater detail below with respect to
In the illustrated embodiment, the actuation assembly 1720 has a relatively flat profile. For example, the actuation assembly 1720 may extend less than about 10 mm (e.g., less than about 5 mm or less than about 2 mm) outwardly from the plate 1702 and/or the septal wall (when implanted). Accordingly, the actuation assembly 1720 may extend less than about 10 mm (e.g., less than about 5 mm or less than about 2 mm) into a heart chamber (e.g., a RA) when implanted in a patient. Without wishing to be bound by theory, the relatively flat profile of the actuation assembly 1720 is expected to reduce a risk of thromboembolic events. Further, in some embodiments the actuation assembly 1720 can also be positioned within a bladder or other membrane (not shown) to fluidly isolate the actuation assembly 1720 from the surrounding environment.
Various aspects of the actuation assembly 1720 can comprise shape-memory material(s) and/or superelastic material(s) configured to at least partially transition from a martensitic phase to an austenitic phase upon application of energy. For example, at least the first actuation element 1722a and the second actuation element 1722b can be composed of a shape memory alloy such as nitinol. The first actuation element 1722a and the second actuation element 1722b can therefore change shape (e.g., expand and/or compress in length, width, etc.) in response to exposure to energy, such as light and/or electrical current, that creates a temperature increase in the material above the transition temperature. In such embodiments, the actuation assembly 1720 can be selectively actuated by applying energy directly or indirectly to the first actuation element 1722a and/or the second actuation element 1722b. In some embodiments, energy can be applied to individual bend regions (e.g., bend regions 1832a-d—
Because the first anchor element 1721a and the second anchor element 1721b are fixedly secured to one another via the spine portion 1725a (e.g., they do not move as the actuation elements move), the first actuation element 1722a pushes the moveable element 1723 towards the second anchor element 1721b as the first actuation element 1722a expands. As a result, the second actuation element 1722b, which remains in a relatively malleable material state, is forced from the partially expanded state towards a compressed state. Therefore, in the illustrated configuration of
In some embodiments, the system 1700 may have a locking mechanism (not shown) to further anchor the actuation assembly 1720 and/or the system 1700 in the desired lumen shape and/or size. In some embodiments, the locking mechanism can be engaged and/or disengaged using (i) the same energy source that is used to adjust the actuation assembly 1720, (ii) the same energy source operating at a different parameter value (e.g., frequency, temperature, etc.), and/or (iii) a different energy source. In some embodiments, the locking mechanism can automatically engage and lock the shunting element 1710 in a given configuration when the actuation assembly 1720 is not being adjusted. In such embodiments, actuation of the actuation assembly 1720 can generate sufficient forces to overcome the locking mechanism.
Altering the shape of the lumen 1712 of the shunting element 1710 may have several benefits, including titrating the rate, velocity, and/or other features of blood flow to more optimally suit a patient's needs. For example, as the shape of a lumen moves from a largely circular cross-section (e.g. as in
The lengths L1 and L2 of the first actuation element 1722a and the second actuation element 1722b, respectively, can be the same or different when the first actuation element 1722a and the second actuation element 1722b are in comparable states. For example, the length L1 of the first actuation element 1722a when it is in the compressed state (
In some embodiments, the actuation assembly 1720 can be biased before implanting the system 1700 into the patient. For example, the actuation assembly 1720 can be biased toward the configuration shown in
The first control wire 1930a and the second control wire 1930b can be selectively actuated to provide energy (e.g., heat) to the first actuation element 1922a or the second actuation element 1922b. For example, the system 1900 can include a first actuator 1940a configured to energize the first control wire 1920a and a second actuator 1940b configured to energize the second control wire 1920b. The first actuator 1940a and the second actuator 1940b can be electronic circuitry or other suitable mechanism(s) that can selectively produce current or other energy. In some embodiments, the first actuator 1940a and the second actuator 1940b can include coils that produce a current in response to magnetic energy. To adjust the shape or size of the lumen 1912, the first actuator 1940a can deliver energy to the first actuation element 1922a via the first control wire 1930a, causing the first actuation element 1922a to expand, as described in detail above with respect to
In some embodiments, each actuation element may include a plurality of independently activatable control wires 1930. Each of the plurality of independently activatable control wires 1930 can be configured to deliver energy to a specific bend region in a corresponding spring element. For example, a first control wire may deliver energy to a first bend region 1932a in the second actuation element 1922b, a second control wire may deliver energy to a second bend region 1932b in the second actuation element 1922b, a third control wire may deliver energy to a third bend region 1932c in the second actuation element 1922b, and a fourth control wire may deliver energy to a fourth bend region 1932d in the second actuation element 1922b. Similarly, a plurality of independently activatable control wires can be configured to deliver energy to individual bend regions in the first actuation element 1922a. Having individual control wires for the individual bend regions enables a user to selectively actuate discrete portions of the actuation elements, which is expected to provide greater precision in control over actuation of the system 1900.
The actuation assembly 2020 can include a first shape memory component 2006, a second shape memory component 2007, a shuttle component 2008 residing between the shape memory components 2006, 2007, and a restriction band 2009 connected to the shuttle component 2008. As best seen in
The first shape memory component 2006 and second shape memory component 2007 can function generally similarly to the actuation elements described above with respect to
The adjustable inner lumen 2130 includes a proximal end portion 2132 positionable within the RA of a human heart. The adjustable inner lumen 2130 extends the longitudinal length of the system 2100 to a distal end portion (not shown). The distal end portion of the lumen 2130 is configured to reside within the LA of the heart when the system 2100 is implanted. Accordingly, the lumen 2130 fluidly connects the LA and the RA of the heart when implanted. The lumen 2130 is defined by a plurality of struts 2134 extending along the axial length of the lumen 2130. The plurality of struts 2134 are generally parallel to a center axis of the lumen 2130. The struts 2134 can comprise a shape-memory material and/or a superelastic material such as nitinol, malleable materials such as annealed or non-annealed stainless steel, cobalt chromium, or other suitable materials. The struts 2134 can be connected to the frame 2110 (e.g., the arms 2112) via one or more connecting struts 2140. The connecting struts 2140 can also comprise a shape-memory material and/or a superelastic material such as nitinol, malleable materials such as annealed or non-annealed stainless steel, cobalt chromium, or other suitable materials. As described below with reference to
The lumen 2130 is further defined by an inner membrane 2133. In some embodiments, the inner membrane 2133 forms a sheath around the struts 2134 (e.g., the struts 2134 can be embedded within the inner membrane 2133). In other embodiments, the struts 2134 can be positioned adjacent to but not encased within the inner membrane 2133. For example, the struts 2134 can be internal to the inner membrane 2133 (e.g., within the lumen 2130) or external to the inner membrane 2133 (e.g., outside the lumen 2130). When the struts 2134 are not encased within the inner membrane 2133, the struts 2134 can be otherwise connected to the inner membrane 2133, although in other embodiments the struts 2134 are not connected to the inner membrane 2133. Regardless of the relative positioning of the struts 2134 and the inner membrane 2133, the inner membrane 2133 can form a single and/or continuous membrane with the outer membrane 2114 of the frame 2110 (in such embodiments, the outer membrane 2114 and the inner membrane 2133 can be collectively referred to as a single or unitary membrane). The volume of space between the outer membrane 2114 and the inner membrane 2133 can form a generally toroidal shaped chamber 2150, as described in greater detail below. The inner membrane 2133 can comprise the same material as the outer membrane 2114 of the frame 2110. For example, the inner membrane 2133 can be a biocompatible and/or anti-thrombogenic material such as ePTFE and/or an elastomeric material that is at least partially stretchable and/or flexible. For example, in one embodiment, the inner membrane 2133 is ePTFE and forms a sheath around the struts 2134. In some embodiments, the inner membrane 2133 and the outer membrane 2114 can comprise different materials. In some embodiments, the system 2100 has two, three, four, five, six, seven, eight, nine, ten, eleven, and/or twelve struts 2134. As described in greater detail with respect to
As described above, the volume between the outer membrane 2114 of the frame 2110 and the inner membrane 2133 of the adjustable inner lumen 2130 defines a generally toroidal shaped chamber 2150. The chamber 2150 can be fluidly isolated from the interior of the lumen 2130 via the inner membrane 2133. The chamber 2150 can also be fluidly isolated from the environment surrounding the system 2100 via the outer membrane 2114. Accordingly, in some embodiments, the system 2100 is configured to prevent blood from flowing into the chamber 2150. In some embodiments, the chamber 2150 can contain a compressible and/or displaceable liquid, gas, and/or gel. Accordingly, as the diameter of the lumen 2130 is adjusted, the liquid or gas can either be compressed, expanded, and/or displaced. The chamber 2150 can also house one or more electronic components (e.g., battery, supercapacitor, etc.). In such embodiments, the electronic components can be electrically isolated from other system components.
Referring to
In various embodiments, system 2100 is configured to adjust from a first configuration to a second configuration. In the first configuration, the lumen 2130 has a first substantially constant diameter. In the second configuration, the lumen 2130 has a second substantially constant diameter different than the first substantially constant diameter. The lumen may have a substantially constant diameter along all or substantially all of its entire length. In other embodiments, however, the lumen may have a substantially constant diameter along only a major portion of its length. For example, the lumen diameter may be substantially constant along the portion which extends through the septal wall. In another example, the lumen has a substantially constant diameter along its entire length, and has additional features adjacent to the lumen on one or both ends, such as a flare, funnel, taper, or the like. For example, as will be described in greater detail below, system 2100 shows the lumen 2130 having a funnel shaped inflow component 2137 configured for fluid communication with a left atrium of a heart (not shown) and a cylindrical shaped outflow portion 2139 configured for fluid communication with the right atrium of a heart (not shown).
Although
The system 2100 can be adjusted between the configurations shown in
In some embodiments, the system 2100 can be adjusted using an inflatable balloon intravascularly delivered proximate the system 2100. For example, a balloon (not shown) can be delivered via a catheter and positioned within the lumen 2130. Inflating the balloon can push the struts 2134 radially outward, enlarging the lumen (e.g., transitioning from the configuration shown in
In some embodiments, the system 2100 can be adjusted using an actuation assembly implanted with the device (not shown). In some embodiments, the actuation assembly is included on the system 2100 and can actively adjust the inner lumen diameter by actuating one or more of the connecting struts 2140, which in turn cause the struts 2134 to change position. In some embodiments, for example, the actuation assembly, when actuated, pulls the proximal end portion 2132 distally, causing the struts 2134 to bend as described above with respect to
In addition to the diameter of the lumen, the shape of the lumen can also promote flow through system 2100. For example, referring back to
When the system 2100 is implanted in a heart, blood flows into the lumen 2130 at the funnel shaped inflow component 2137 (e.g., through the distal inflow aperture), through the cylindrical shaped outflow portion 2139, and into the RA. In the exemplary embodiment, the combination of the funnel shaped inflow component 2137 and the cylindrical shaped outflow portion 2139 are expected to provide the system 2100 with a number of beneficial flow characteristics. For example, the funnel shaped inflow component 2137 can increase blood flow into the lumen 2130 from the LA. The relatively larger distal inflow aperture allows for the gathering of a larger blood volume. Blood then flows from the relatively larger diameter funnel shaped inflow component 2137 to the relatively smaller diameter cylindrical shaped outflow portion 2139. Based on the Venturi effect (Bernoulli's principle in mathematical terms), pressure decreases downstream and the flow velocity increases as the blood flows from the funnel shaped inflow component 2137 into the relatively smaller diameter cylindrical shaped outflow portion 2139. In the exemplary embodiment, the outflow portion 2139 has a cylindrical shape with a substantially constant diameter along length L1. The cylindrical shaped outflow portion 2139 maintains flow therethrough. By contrast, a funnel-shaped outflow would act as a diffuser. Based on Bernoulli's Principle, an increasing diameter on the outflow would decrease flow velocity. The exemplary cylindrical-shaped outflow reduces swirl effects and turbulence from the inflow while also minimizing pressure increases. Combined, these effects are expected to enhance blood flow between the LA and the RA. Additionally, as illustrated in
One will appreciate from the description herein that other lumen shapes are possible and within the scope of the present technology. In some embodiments, for example, the lumen does not have the funnel shaped inlet component but rather retains a substantially constant diameter along substantially the entire length of the lumen. For example, the lumen can be substantially cylindrical with a substantially constant diameter extending between the distal end portion and the proximal end portion. In other embodiments, the lumen is tapered and has a variable diameter extending between the distal end portion and the proximal end portion. For example, the lumen can have a relatively larger inflow aperture at the distal end portion and relatively smaller outflow aperture at the proximal end portion, with the lumen constantly tapering inward between the inflow aperture and the outflow aperture to form a funnel shape. In yet other embodiments, the lumen can have a generally hourglass shape having a central pinch point. As discussed above, altering the shape of the lumen can affect the rate of the blood flow through the lumen. Accordingly, the shape of the lumen provides an additional mechanism for facilitating increased control over the flow of blood between the LA and the RA through shunts configured in accordance with the present technology.
One will further appreciate from the disclosure herein that other flow control mechanisms can be used with the shunting systems described herein. For example, in some embodiments, the shunting systems can include a gate-like valve that can move between a first position blocking or at least partially blocking a flow lumen and a second position unblocking or at least partially unblocking the flow lumen. In such embodiments, the gate-like valve can be coupled to one or more shape memory elements that can be manipulated using energy, such as energy stored in an energy storage component or energy applied directly to the shape memory element via an energy source positioned external to the patient. As another example, the shunting systems can include one or more shape memory coils wrapped around a portion of the shunting element defining the flow lumen. The shape memory coils can be selectively wound or unwound to restrict (e.g., cinch) or relax (e.g., uncinch) a portion of the flow lumen. In yet other embodiments, the shunting element can include a flexible bladder filled with a fluid or gas. The flexible bladder can be generally toroidal shaped such that it defines a flow lumen therethrough. The fluid or gas can be directed into or out of the bladder to decrease or increase the size of the lumen. In yet other embodiments, the shunting element may incorporate at least partially passive concepts that can adjust a size or shape of the flow lumen based on the pressure differential between two heart chambers. Accordingly, the systems described herein are not limited to the flow control mechanisms and/or shunting devices expressly described herein. Other suitable shunting devices can be utilized and are within the scope of the present technology.
D. Shunting Assemblies with Adjustable Inflow and/or Outflow Orifices
The frame 2412 can further include a plurality of first anchor elements 2414 extending from a first end portion of the frame 2412 and a plurality of second anchor elements 2416 extending from a second end portion of the frame 2412 that is generally opposite the first end portion. In the illustrated embodiment, the plurality of first anchor elements 2414 and the plurality of second anchor elements 2416 extend around the full circumference of the frame 2412, although other embodiments can have different suitable configurations. For example, in other embodiments, the anchor elements 2414 and/or 2416 may be a single element (e.g., a coil-shaped element). The first anchor elements 2414 and the second anchor elements 2416 can engage native tissue to secure the device 2400 in a desired position. For example, the first anchor elements 2414 and the second anchor elements 2416 can secure the device 2400 to a septal wall such that the lumen 2401 fluidly connects the LA and the RA. In such embodiments, the first anchor elements 2414 can be positionable within the RA and configured to engage the RA side of the septal wall, and the second anchor elements 2416 can be positionable in the LA and configured to engage the LA side of the septal wall. A portion of the septal wall can be received between the first anchor elements 2414 and the second anchor elements 2416. In other embodiments, the orientation of the device can be reversed such that the first anchor elements 2414 are positionable in the LA and the second anchor elements 2416 are positionable in the RA. In some embodiments, the first anchor elements 2414 and/or the second anchor elements 2416 are integral with the frame 2412. In other embodiments, the first anchor elements 2414 and/or the second anchor elements 2416 are secured to the frame 2412 using techniques known in the art (e.g., welding, gluing, suturing, etc.).
The shunting element 2410 can include a membrane 2430 coupled to (e.g., affixed, attached, or otherwise connected) to the frame 2412. In some embodiments, the membrane 2430 is flexible and can be made of a material that is impermeable to or otherwise resists blood flow therethrough. In some embodiments, for example, the membrane 2430 can be made of a thin, elastic material such as a polymer. For example, the membrane 2430 can be made of polytetrafluoroethylene (PTFE), ePTFE (ePTFE), silicone, nylon, polyethylene terephthalate (PET), polyether block amide (pebax), polyurethane, blends or combinations of these materials, or other suitable materials. The membrane 2430 can cover and/or enclose at least a portion of the shunting element 2410, such as the interior or exterior surface of the shunting element 2410 between a first end portion positionable in the LA and a second end portion positionable in the RA. The membrane 2430 can extend circumferentially around the frame 2412 to at least partially surround and enclose the lumen 2401, thereby defining (at least in part) a flow path for blood when implanted across the septal wall.
In some embodiments, the membrane 2430 includes a first membrane portion 2432 coupled to a second membrane portion 2434. The first membrane portion 2432 can be operably coupled to and/or extend around a central portion of the frame 2412 (e.g., the portion having the first struts 2411). In some embodiments, the first membrane portion 2432 can also include a flange portion 2433 that is operably coupled to and/or extending around the second anchor elements 2416. The second membrane portion 2434 can be operably coupled to and/or extend around the plurality of second struts 2413 angled radially inward towards the orifice 2405. The second membrane portion 2434 can be at least partially conical or funnel shaped and extend past the second struts 2413 so that at least a portion of the second membrane portion 2434 is positioned over and partially covers the lumen 2401, thereby defining an orifice 2405. The first membrane portion 2432 can be secured to the second membrane portion 2434 via suturing or other suitable techniques. In other embodiments, the membrane 2430 is a unitary membrane comprising both the first membrane portion 2432 and the second membrane portion 2434.
The device 2400 can further include an actuation assembly 2418 configured to change a geometry (e.g., a size and/or shape) of the orifice 2405. The actuation assembly 2418 can include a flow control element 2420, a plurality of first actuation elements 2422a, and a plurality of second actuation elements 2422b. As will be described in greater detail below, the first actuation elements 2422a and/or the second actuation elements 2422b can be selectively actuated to change a geometry of the flow control element 2420. In turn, this adjusts (e.g., stretches and/or compresses) the second membrane portion 2434 surrounding and defining the orifice 2405. As previously described, blood can flow between the LA and the RA via the lumen 2401 when the device 2400 is implanted across a septal wall. Accordingly, changing a geometry of the orifice 2405 is expected to change the relative flow resistance and/or the amount of blood flowing between the LA and the RA.
The flow control element 2420 of device 2400 generally extends around an outer circumference of the orifice 2405 and at least partially defines the geometry of the orifice 2405. For example, the flow control element 2420 can be an annular (e.g., ring-like) structure coupled to the second membrane portion 2434. In embodiments in which the orifice 2405 has other shapes (e.g., square), the flow control element 2420 can have a generally similar shape (e.g., square) such that the flow control element 2420 extends around an outer perimeter of the orifice 2405. The flow control element 2420 can be flexible such that it can expand and contract to change a geometry (e.g., a diameter) of the orifice 2405. For example, when the flow control element 2420 moves in a first manner (e.g., expands), the diameter of the orifice 2405 increases, thereby decreasing the flow resistance through the lumen 2401. When the flow control element 2420 moves in a second manner opposing the first manner (e.g., contracts), the diameter of the orifice 2405 decreases, thereby increasing the flow resistance through the lumen.
The shape of the flow control element 2420 can be at least partially controlled via a plurality of first actuation elements 2422a and a plurality of second actuation elements 2422b. As described in detail with respect to
The first actuation elements 2422a and the second actuation elements 2422b can be composed of a shape memory material, such as a shape memory alloy (e.g., nitinol). Accordingly, the first actuation elements 2422a and the second actuation elements 2422b can be transitionable between a first material state (e.g., a martensitic state, a R-phase, etc.) and a second material state (e.g., a R-phase, an austenitic state, etc.). In the first state, the first actuation elements 2422a and the second actuation elements 2422b may be relatively deformable (e.g., plastic, malleable, compressible, expandable, etc.). In the second state, the first actuation elements 2422a and the second actuation elements 2422b may have a preference toward a specific manufactured geometry (e.g., shape, length, and/or or dimension). The first actuation elements 2422a and the second actuation elements 2422b can be transitioned between the first state and the second state by applying energy (e.g., heat) to the actuation elements to heat the actuation elements above a transition temperature. In some embodiments, the transition temperature for both the first actuation elements 2422a and the second actuation elements 2422b is above an average body temperature. Accordingly, both the first actuation elements 2422a and the second actuation elements 2422b are typically in the deformable first state when the device 2400 is implanted in the body until they are heated (e.g., actuated).
If the actuation elements (e.g., the first actuation elements 2422a) are deformed relative to their manufactured geometry while in the first state, heating the actuation elements (e.g., the first actuation elements 2422a) above their transition temperature causes the actuation elements to transition to the second state and therefore transition from the deformed shape towards a manufactured shape. As described in detail below, heat can be applied to the actuation elements via RF heating, resistive heating, or the like. In some embodiments, the first actuation elements 2422a can be selectively heated independently of the second actuation elements 2422b, and the second actuation elements 2422b can be selectively heated independently of the first actuation elements 2422a. In some embodiments, portions of the actuation elements (e.g., the first nitinol portion 2422a1 or the second nitinol portion 2422a2 (
Each first actuation element 2422a can further comprise (or be coupled to) a first clip element 2524a having a first fixation element 2526a. The first fixation element 2526a can secure the corresponding first actuation element 2422a to the frame 2412 or another suitable component of the device 2400 (
Likewise, each second actuation element 2422b can further comprise (or be coupled to) a second clip element 2524b having a second fixation element 2526b. The second fixation element 2526b can secure the corresponding second actuation element 2422b to the frame 2412 or another suitable component of the device 2400 (
The device 2400 can be repeatedly transitioned between the second configuration and the third configuration. For example, the device 2400 can be returned to the second configuration from the third configuration by heating the first actuation elements 2422a above their transition temperature once the second actuation elements 2422b have returned to a deformable first state (e.g., by allowing the second actuation elements 2422b to cool below the transition temperature after being heated, etc.). Heating the first actuation elements 2422a above their transition temperature causes the first actuation elements to move towards their manufactured geometry, which in turn pushes the flow control element 2420 radially inward and transitions the device 2400 to the second configuration (
In some embodiments, device 2400 can also be transitioned to or from intermediate configurations between the second and third configurations. In some embodiments, for example, the device 2400 can initially transition from a first composite configuration into the second configuration, the third configuration, or another configuration (e.g., the device may be transitioned to the third configuration or another configuration before being actuated to the second configuration). In some embodiments, the configuration of device 2400 can also be altered without inducing a change in material state of either the first actuation elements 2422a or the second actuation elements 2422b. This may be accomplished, for example, via direct mechanical methods that apply external forces to a component or portion of the device (e.g., via a balloon expansion of flow control element 2420, similar to previously described with respect to
Accordingly, the device 2400 can be selectively transitioned between a variety of configurations by selectively actuating some or all of either the first actuation elements 2422a or the second actuation elements 2422b. After actuation, the device 2400 can be configured to substantially retain the given configuration until further actuation of the opposing actuation elements. In some embodiments, the device 2400 can be transitioned to intermediate configurations between the second configuration and the third configuration (e.g., the first configuration) by heating some, but not all, of either the first actuation elements 2422a or the second actuation elements 2422b.
As provided above, heat can be applied to the actuation elements via RF heating, resistive heating, or the like. In some embodiments, the first actuation elements 2422a can be selectively heated independently of the second actuation elements 2422b, and the second actuation elements 2422b can be selectively heated independently of the first actuation elements 2422a. For example, in some embodiments, the first actuation elements 2422a are on a first electrical circuit for selectively and resistively heating the first actuation elements 2422a and the second actuation elements 2422b are on a second electrical circuit for selectively and resistively heating the second actuation elements 2422b. As described in detail above, selectively heating the first actuation elements 2422a reduces the diameter of the orifice 2405 and selectively heating the second actuation elements 2422b increases the diameter of the orifice 2405. In some embodiments, each individual first actuation element 2422a is on its own selectively and independently activatable electric circuit, and each individual second actuation element 2422b is on its own selectively and independently activatable electric circuit. Without being bound by theory, this permits individual actuation elements to be selectively actuated, thereby increasing the granularity of potential adjustments to the diameter of the orifice 2405.
In some embodiments, actuation elements may be configured differently than as described above. For example, in some embodiments both the first actuation elements 2422a and second actuation elements 2422b are compressed (or alternatively, expanded) from their manufactured geometry when placed into an initial composite configuration. For example, each set of actuation elements may be compressed (or alternatively, expanded) a different amount. Variation embodiments may include more than two sets of actuation elements that are manufactured to have two or more manufactured geometries.
However, in contrast with the device 2400 described previously, the device 2600 incorporates an actuatable flow control element 2620 disposed around the orifice 2605 (e.g., the flow control element 2620 is an annular actuation element). For example, the flow control element 2620 can be composed of a shape memory material, such as a shape memory alloy (e.g., nitinol). Accordingly, the flow control element 2620 can be transitionable between a first material state (e.g., a martensitic state, a R-phase, etc.) and a second material state (e.g., a R-phase, an austenitic state, etc.). In the first state, the flow control element 2620 may be deformable (e.g., plastic, malleable, compressible, expandable, etc.). In the second state, the flow control element 2620 may have a preference toward a specific manufactured geometry (e.g., shape, diameter, and/or dimension). The flow control element 2620 can be transitioned between the first state and the second state by applying energy to heat the flow control element 2620 above a transition temperature. Heating the flow control element 2620 above its transition temperature to transform the material to the second state causes the flow control element 2620 to move towards its manufactured geometry. If the flow control element 2620 is deformed relative to its manufactured geometry while in the first state, these deformations may be partially or completely recovered when material transitions into the second state. In some embodiments, the transition temperature for the flow control element 2620 is above an average body temperature. In some embodiments, the flow control element 2620 can be heated via RF energy, resistive heating, and the like. The flow control element 2620 can be coupled to the membrane 2630 such that dimensional adjustments to the flow control element 2620 impart a corresponding dimensional change to the orifice 2605.
The device 2600 further includes a plurality of actuation elements 2622 disposed radially around the flow control element 2620. The plurality of actuation elements 2622 can be generally similar to the plurality of first actuation elements 2422a described above with respect to
The device 2600 can be transitioned between a variety of configurations by selectively heating either the flow control element 2620 or the actuation elements 2622 (or, alternatively, by directly applying mechanical forces to flow control element 2620 while it is a relatively deformable (e.g., martensitic) material state). The illustrated configuration, for example, may be a composite configuration in which both the flow control element 2620 and the actuation elements 2622 are deformed relative to their manufactured geometries. For example, the actuation elements 2622 may be compressed (e.g., shortened) relative to their manufactured geometry, and the flow control element 2620 may be compressed (e.g., having a smaller diameter) relative to its manufactured geometry. Accordingly, to increase the diameter of the orifice, the flow control element 2620 can be heated above its transition temperature (while the actuation elements remain below the transition temperature) to transition from a first state (e.g., a martensitic state) to a second state (e.g., austenitic state), inducing a change in configuration towards its manufactured geometry due to the shape memory effect. To decrease the diameter of the orifice, the actuation elements 2622 can be heated above the transition temperature (while the flow control element 2620 remains below its transition temperature) to transition from a first state (e.g., martensitic state) to a second state (e.g., austenitic state), inducing a change in configuration towards their manufactured geometry due to the shape memory effect. In other embodiments, the actuation elements 2622 may be expanded (e.g., lengthened) relative to their manufactured geometry, and the flow control element 2620 may be expanded (e.g., having a larger diameter) relative to its manufactured geometry when the device 2600 is in the composite configuration. In such embodiments, the actuation elements 2622 are selectively heated to increase the diameter of the orifice 2605, and the flow control element 2620 is selectively heated to decrease the diameter of the orifice 2605. In some embodiments, stabilization features (not shown) may be included proximate to actuation elements 2622 to restrict the movement of the actuation elements in a desired way (e.g., restrict the movement to be solely or primarily the plane of elements' long axis). Such features may facilitate the transfer of forces and/or movements between various aspects of device 2600, for example between actuation elements 2622, flow control element 2620, and membrane 2630. In embodiments, any number of flow control elements and sets of actuation elements may be used in combination with one another.
The actuation assembly 2718 includes two independently actuatable flow control elements. In particular, the actuation assembly 2718 includes a first actuatable flow control element 2720a and a second actuatable flow control element 2720b. Accordingly, in some embodiments, the device 2700 does not include other actuation elements that are distinct from the flow control elements 2720a, 2720b (e.g., such as actuation elements 2422a, 2422b, described with respect to
The first flow control element 2720a and the second flow control element 2720b can be composed of a shape memory material, such as a shape memory alloy (e.g., nitinol). Accordingly, the first flow control element 2720a and the second flow control element 2720b can be transitionable between a first state (e.g., a martensitic state, a R-phase, etc.) and a second state (e.g., a R-phase, an austenitic state, etc.). In a first state, the first flow control element 2720a and the second flow control element 2720b may be deformable (e.g., malleable, compressible, expandable, etc.). In a second state, the first flow control element 2720a and the second flow control element 2720b may have a preference toward a specific manufactured geometry (e.g., shape, length, and/or or dimension). The first flow control element 2720a and the second flow control element 2720b can be transitioned between a first state and a second state by applying energy to the actuation elements to heat the flow control elements above a transition temperature. In some embodiments, the transition temperature for both the first flow control element 2720a and the second flow control element 2720b is above an average body temperature. Accordingly, both the first flow control element 2720a and the second flow control element 2720b are typically in the deformable first state when the device 2700 is implanted in the body except for when they are heated (e.g., actuated).
Heating the flow control elements (e.g., the first flow control element 2720a) above their transition temperature causes the flow control elements to transform to the second state and therefore transition towards their manufactured geometries. If the flow control elements (e.g., the first flow control element 2720a) are deformed while in the first state, these deformations may be partially or completely recovered when material transitions into the second state. Heat can be applied to the flow control elements via RF heating, resistive heating, or the like. In some embodiments, the first flow control element 2720a can be selectively heated independently of the second flow control element 2720b, and the second flow control element 2720b can be selectively heated independently of the first flow control element 2720a. As described in detail below, selectively heating the first flow control element 2720a reduces the diameter of the orifice 2705 and selectively heating the second flow control element 2720b increases the diameter of the orifice 2705. Although two flow control elements are shown in
The device 2700 can be transitioned between a variety of configurations by selectively heating either the first flow control element 2720a or the second flow control element 2720b. The illustrated configuration may be a composite configuration in which both the first flow control element 2720a and the second flow control element 2720b are deformed relative to their manufactured geometries. For example, the first flow control element 2720a may be expanded (e.g., having a greater diameter) relative to its manufactured geometry, and the second flow control element 2720b may be compressed (e.g., having a smaller diameter) relative to its manufactured geometry. Accordingly, to increase the size (e.g., diameter) of the orifice 2705, the second flow control element 2720b can be heated above its transition temperature (while the first flow control element remains below the transition temperature) to transition from a first relatively malleable state (e.g., martensitic state) to a second state (e.g., austenitic state) and move towards its manufactured geometry. To decrease the size (e.g., diameter) of the orifice 2705, the first flow control element 2720a can be heated above the transition temperature (while the second flow control element 2720b remains below its transition temperature) to transition from a first relatively malleable state (e.g., martensitic state) to a second state (e.g., austenitic state) and move towards its manufactured geometry.
Returning to
In this embodiment, the system 2900 can further comprise a second membrane 2932 engaged with the frame 2912 and first membrane 2930 and extending at least partially over components of the system 2900 that are spaced apart from the shunting element 2910 (e.g., anchor(s), energy storage component(s), etc.). The second membrane 2932 may be composed of, for example, a braided mesh or other suitable material. During operation of the system 2900, the second membrane 2932 is configured to at least partially isolate the energy storage component(s) from blood within the RA and LA. This arrangement is expected to further inhibit thrombus formation after implantation of the system 2900 within the patient. The second membrane 2932 is an optional component that may have a different configuration/arrangement than the embodiment shown in
The shunting element 3002 can be a frame including a first annular element 3006a at the first end portion 3003a and a second annular element 3006b at the second end portion 3003b. The first and second annular elements 3006a-b can each extend circumferentially around the lumen 3004 to form a stent-like frame structure. In the illustrated embodiment, the first and second annular elements 3006a-b each have a serpentine shape with a plurality of respective apices 3008a-b. The apices 3008a-b can be curved or rounded. In other embodiments, the apices 3008a-b can be pointed or sharp such that the first and second annular elements 3006a-b have a zig-zag shape. Optionally, the first and second annular elements 3006a-b can have different and/or irregular patterns of apices 3008a-b, or can be entirely devoid of apices 3008a-b. The first and second annular elements 3006a-b can be coupled to each other by a plurality of struts 3010 extending longitudinally along the shunting element 3002. The struts 3010 can be positioned between the respective apices 3008a-b of the first and second annular elements 3006a-b.
The system 3000 further includes a membrane 3012 operably coupled (e.g., affixed, attached, or otherwise connected) to the shunting element 3002. In some embodiments, the membrane 3012 is flexible and can be made of a material that is impermeable to or otherwise resists blood flow therethrough. In some embodiments, for example, membrane 3012 can be made of a thin, elastic material such as a polymer. For example, the membrane 3012 can be made of PTFE, ePTFE, silicone, nylon, PET, polyether block amide (pebax), polyurethane, blends or combinations of these materials, or other suitable materials.
The membrane 3012 can cover at least a portion of the shunting element 3002, such as the exterior surface of the shunting element 3002 between the first end portion 3003a and the second end portion 3003b. The membrane 3012 can extend circumferentially around the shunting element 3002 to at least partially surround and enclose the lumen 3004. For example, in the illustrated embodiment, the membrane 3012 extends between the first and second annular elements 3006a-b and over the struts 3010. The membrane 3012 can couple the first and second annular elements 3006a-b to each other, in combination with or as an alternative to the struts 3010. The membrane 3012 can extend past the first end portion 3003a and/or the first annular element 3006a (e.g., as best seen in
The membrane 3012 includes an aperture 3014 formed therein. When the membrane 3012 is coupled to the shunting element 3002, the aperture 3014 can be at least generally aligned with or otherwise overlap the lumen 3004 to permit blood flow therethrough. In some embodiments, the aperture 3014 is positioned at or near the first end portion 3003a of the shunting element 3002. In other embodiments, the aperture 3014 can be positioned at or near the second end portion 3003b. Additionally, although
The geometry (e.g., size and/or shape) of the aperture 3014 can be varied by deforming (e.g., stretching and/or compressing) or otherwise moving the portions of the membrane 3012 surrounding the aperture 3014. The change in geometry of the aperture 3014 can affect the amount of blood flow through the lumen 3004. In some embodiments, depending on the size of the aperture 3014 relative to the size of the lumen 3004, blood flow through the lumen 3004 can be partially or completely obstructed by the membrane 3012. Accordingly, an increase in the size (e.g., a diameter, an area) of the aperture 3014 can increase the amount of blood flow through the lumen 3004, while a decrease in the size of the aperture 3014 can decrease the amount of blood flow.
The system 3000 can include an actuation assembly 3015 operably coupled to the aperture 3014 to selectively adjust the size thereof. The actuation assembly 3015 can include an actuation mechanism 2016 and a string element 3018 (e.g., a cord, thread, fiber, wire, tether, ligature, or other flexible elongated element). The actuation mechanism 3016 is coupled to the string element 3018 around the aperture 3014 for controlling the size thereof. For example, the string element 3018 can include a loop portion 3020 surrounding the aperture 3014 and a connecting portion 3022 coupling the loop portion 3020 to the actuation mechanism 3016. In some embodiments, the loop portion 3020 and the connecting portion 3022 are different portions of one contiguous elongated element (e.g., arranged similarly to a lasso or snare) that attain their relative shapes (e.g., an elliptical, loop-like shape) as a consequence of how they are connected to the system 3000. In other embodiment, the loop portion 3020 and the connecting portion 3022 can be separate elements that are directly or indirectly coupled to each other.
One or more portions of the string element 3018 (e.g., the loop portion 3020) can be coupled to the portion of the membrane 3012 near the aperture 3014. In the illustrated embodiment, the string element 3018 (e.g., loop portion 3020) passes through a plurality of openings or holes 3024 (e.g., eyelets) located near the peripheral portion of the aperture 3014. The openings 3024 can be coupled to the shunting element 3002 (e.g., to the first end portion 3003a and/or first annular element 3006a) via a plurality of flexible ribs 3026 (e.g., sutures, strings, threads, metallic structures, polymeric structures, etc.). In other embodiments, the openings 3024 are formed in or coupled directly to the membrane 3012 such that the ribs 3026 are omitted.
In some embodiments, the string element 3018 has a lasso- or noose-like configuration in which the loop portion 3020 can be tightened to a smaller size or loosened to a larger size by making an adjustment to (e.g., translating, rotating, applying or releasing tension, etc.) on the connecting portion 3022. In some embodiments, a motion caused by the adjustment of connecting portion 3022 creates an induced motion in loop portion 3020 (e.g., a motion that results in the loop portion 3020 shifting to a larger or a smaller size). Due to the coupling between the string element 3018 and the membrane 3012, the size of the aperture 3014 (e.g., a diameter, an area) can change along with the size of the loop portion 3020 such that the size of the aperture 3014 increases as the size of the loop portion 3020 increases, and decreases as the size of the loop portion 3020 decreases. For example, as the size of the loop portion 3020 decreases, the portions of the membrane 3012 surrounding the aperture 3014 can be cinched, stretched, or otherwise drawn together by the loop portion 3020 so that the size of the aperture 3014 decreases. Conversely, as the size of the loop portion 3020 increases, the portions of the membrane 3012 surrounding the aperture can be released, loosened, stretched, or otherwise allowed to move apart so that the size of the aperture 3014 increases. Accordingly, the actuation mechanism 3016 can adjust the size of the loop portion 3020, and thus the size of the aperture 3014, by controlling the amount of force (e.g., tension) applied to the loop portion 3020 via the connecting portion 3022. For example, in some embodiments, the actuation mechanism 3016 increases the size of the loop portion 3020 and aperture 3014 by increasing the amount of force applied to the connecting portion 3022, and decreases the size of the loop portion 3020 and aperture 3014 by decreasing the amount of applied force.
In other embodiments, the system 3000 can implement different mechanisms for mechanically and/or operably coupling the actuation mechanism 3016, the loop portion 3020, and the connecting portion 3022. For example, there can be an inverse relationship between these components, e.g., the actuation mechanism 3016 can increase the size of the loop portion 3020 and aperture 3014 by increasing the amount of force applied to the connecting portion 3022, and can decrease the size of the loop portion 3020 and aperture 3014 by decreasing the amount of applied force. In some embodiments, changes in the size of the loop portion 3020 and aperture 3014 are created via the actuation mechanism 3016 translating, rotating, or otherwise manipulating the connecting portion 3022 in a way that does not substantially increase or decrease the amount of force applied to the connecting portion 3022. In other embodiments, the adjustment to the connecting portion 3022 made by the actuation mechanism 3016 can result in an alteration of the shape of (rather than the size of) loop portion 3020 and aperture 3014.
In some embodiments, the connecting portion 3022 can be surrounded by a relatively stiff conduit 3034 (e.g., a plastic or metallic hypotube, shown in
The actuation mechanism 3016 can be configured in a number of different ways. In some embodiments, for example, the actuation mechanism 3016 includes one or more motors, such as electromagnetic motors, implanted battery and mechanical motors, MEMS motors, micro brushless DC motors, piezoelectric based motors, solenoids, and other motors. In other embodiments, the actuation mechanism 3016 includes one or more shape memory elements. For example, referring to
In some embodiments, the connecting portion 3022 can be received within the conduit 3034 (e.g., a flexible tube). The conduit 3034 can serve as a guide for the connecting portion 3022. In some embodiments, the conduit 3034 also provides mechanical stabilization that impacts how the loop portion 3020 and aperture 3014 move in response to manipulation of the connecting portion 3022. The conduit 3034 can be coupled to the housing 3032 or to another component of the system 3000 (e.g., in embodiments wherein the housing 3032 is omitted).
The movement of the shuttle element 3030 can be actuated by the first and second shape memory actuation elements 3028a-b. For example, the first and second shape memory actuation elements 3028a-b can each be configured to change in shape in response to a stimulus such as heat or mechanical loading. In some embodiments, the first and second shape memory actuation elements 3028a-b are each manufactured or otherwise configured to approach (e.g., change in shape, deform, transform, etc.) a relatively lengthened configuration upon application of heat. In other embodiments, the first and second shape memory actuation elements 3028a-b are each manufactured or otherwise configured to approach a relatively shortened configuration upon application of heat. Optionally, one shape memory actuation element can approach a relatively lengthened configuration when heated, while the other shape memory actuation element can approach a relatively shortened configuration when heated. In some embodiments, at least one shape memory actuation element is manufactured so that, at a first temperature (e.g., body temperature), it is relatively more thermoelastically deformable in response to a fixed force or stress than it would be at a second temperature. The second temperature can be a higher temperature (e.g., a temperature resulting from the application of heat to an element) than the first temperature.
The shape change (e.g., due to deformation by externally-applied forces, due to heating that results in a deformation related to the shape memory effect, etc.) of the first and/or second shape memory actuation elements 3028a-b can actuate movement of the shuttle element 3030 relative to the housing 3032. In some embodiments, the first and second shape memory actuation elements 3028a-b, when at an unheated temperature (e.g., at or close to body temperature), are relatively more thermoelastically deformable as described above. In such embodiments, actuation (e.g., expansion/lengthening) of one shape memory actuation element via heating can move shuttle element 3030 in such a way that deforms/compresses the other shape memory actuation element.
Referring initially to
Referring next to
Referring to
It will be appreciated that the system 3000 can be configured in a number of different ways. In some embodiments, for example, the system 3000 can include multiple membrane structures and/or materials. For example, a first membrane can interface with a first portion of the system 3000 (e.g., between first and second annular elements 3006a-b) and a second membrane can interface with a second portion of the system 3000 (e.g., between first annular element 3006a and a string element 3018). In such embodiments, the first and second membranes can be made of different materials having different material properties (e.g., flexibility, elasticity, permeability, tear strength, etc.). This approach is expected to be advantageous in embodiments where different material properties are optimal or otherwise beneficial for different regions of the system 3000. For example, flexibility may be an important characteristic in one region of the system 3000, while in a second region, lack of permeability may be more important than flexibility. The system 3000 can include any suitable number of membrane structure and/or materials. Optionally, some portions of the system 3000 can include multiple (e.g., overlapping) membranes made of the same material or different materials.
The actuation mechanism 3016 can be configured in a number of different ways. For example, in some embodiments the first and/or second shape memory actuation elements 3028a-b can be manufactured or otherwise configured to approach a relatively shortened configuration rather than a relatively lengthened configuration when heated. As a result, heat can be applied to the first shape memory actuation element 3028a to retract more of the string element 3018 into the housing 3032, and heat can be applied to the second shape memory actuation element 3028b to release more of the string element 3018 from the housing 3032. Additionally, although
In some embodiments, the first and second shape memory actuation elements 3028a-b are positioned on the same side of the shuttle element 3030. In such embodiments, one shape memory actuation element can be manufactured such that when it is heated it moves towards a relatively lengthened/expanded configuration, and the second shape memory actuation element can be manufactured such that when it is heated it moves towards a relatively shortened/contracted configuration. In other embodiments, any number of shape memory actuation elements that have been manufactured to have similar or dissimilar original geometric configurations may be utilized.
In some embodiments, the string element 3018 itself acts as an actuation mechanism. In such embodiments, any additional actuation mechanism (e.g., actuation mechanism 3016) can be omitted. For example, an embodiment may consist of a string element 3018 that is composed entirely of a loop portion 3020 (e.g., there is no connecting portion 3022) that interfaces with openings or holes 3024 (e.g., eyelets). The loop portion 3020 may also interface directly or indirectly with membrane 3012 so as to form aperture 3014. The string element 3018 can include a shape memory material (e.g., a nitinol wire or strut). In a mode of operation, the size and/or shape of the loop portion 3020 can be altered to vary the shape of the aperture 3014. For example, a shape memory material comprising the loop portion 3020 can be manufactured to have a relatively small geometry (e.g., a small diameter). Prior to or following implantation, a force can be applied (e.g., a radial outward force provided by an expanding balloon) to the loop portion 3020 to deform it into a configuration with a relatively larger geometry. Subsequently, heat can be applied to the shape memory loop portion 3020 to induce a shape change towards its relatively smaller manufactured geometry. A series of similar operations can be performed over a period of time to allow a care provider to change an aperture size multiple times within a range of possible sizes. In other embodiments, the shape memory material comprising the loop portion 3020 can be manufactured to have a relatively large geometry. Prior to or following implantation, a force can be applied (e.g., a compressive force from a snare tool) to the loop portion 3020 to deform it into a configuration with a relatively smaller geometry. Subsequently, heat can be applied to the shape memory loop portion to induce a shape change towards its relatively larger manufactured geometry.
In some embodiments, the string element 3018 includes two or more shape memory elements that have been coupled together mechanically (e.g., with welds, sutures, glue/adhesives, rivets/crimps, etc.) in a way such that the two or more elements are electrically and/or thermally insulated from one another. In such embodiments, for example, a first shape memory element may be manufactured to have a relatively larger geometry, and a second shape memory element may be manufactured to have a relatively smaller geometry. As these elements are mechanically coupled, a heat-driven actuation of one element towards its original geometric configuration may drive a similar motion in the non-heated element, since the non-heated element will remain in a relatively more thermoelastically deformable material phase. As such, the size of the loop portion 3020, and thereby the size of aperture 3014, may be adjusted to be both larger and smaller using energy applied to different portions of the string element 3018. In such embodiments, the size of the loop portion 3020 can also be altered by applying an external force (e.g., via an expandable balloon).
In embodiments of the present technology that utilize heat or another form of energy applied to a shape memory element or another component of the system, the energy/heat can be applied both invasively (e.g., via a catheter delivering laser, radiofrequency, or another form of energy, via an internal stored energy source such as a supercapacitor, etc.), non-invasively (e.g., using radiofrequency energy delivered by a transmitter outside of the body, by focused ultrasound, etc.), or through a combination of these methods.
Referring first to
The adjustable structure 3102 can be made of a flexible and/or relatively malleable material (e.g., a metal or a polymer) configured to deflect and/or deform (e.g., elastically and/or plastically deform) when force is applied thereto. In one particular example, the adjustable structure 3102 can be an annealed stainless-steel wire. As another particular example, the adjustable structure 3102 can be a polyurethane string or suture. As a result, when force is applied to the adjustable structure 3102 (e.g., by actuation mechanism 3101), the adjustable structure 3102 can change in geometry (e.g., size and/or shape) to produce a corresponding change in geometry of the aperture 3104. For example, as the size (e.g., diameter) of the adjustable structure 3102 decreases, the portions of the membrane surrounding the aperture 3104 can be cinched, stretched, loosened, or otherwise drawn together by the adjustable structure 3102 so that the size of the aperture 3104 decreases. Conversely, as the size of the adjustable structure 3102 increases, the portions of the membrane surrounding the aperture 3104 can be released, loosened, stretched, or otherwise allowed to move apart so that the size of the aperture 3104 increases. In some embodiments, the adjustable structure 3102 is transformable between a plurality of different configurations having different geometries, such as an expanded configuration having a relatively large size (e.g., as measured by diameter, cross-sectional area) and/or a compressed configuration having a relatively small size. When the adjustable structure 3102 is in the expanded configuration, the aperture 3104 can provide relatively lower resistance to fluid flow therethrough, thus permitting a greater amount of fluid flow. When the adjustable structure 3102 is in the compressed configuration, the aperture 3104 can provide relatively increased resistance to fluid flow therethrough, thus partially or completely inhibiting the volume of fluid flow.
Optionally, the adjustable structure 3102 can be made of a shape memory material such as nitinol. In such embodiments, for example, changes to the size and/or geometry of the adjustable structure 3102 (and therefore the aperture 3104) can be induced both by applying external stresses to the adjustable structure 3102 and/or by inducing internal stresses in the adjustable structure 3102 via the application of energy (e.g., heating the adjustable structure 3102 beyond a transition temperature that results in at least a temporary alteration of the material state).
The actuation mechanism 3101 can be configured to selectively change the geometry of the adjustable structure 3102 in order to modulate the size of the aperture 3104 and, accordingly, the relative volume of fluid flow therethrough. In some embodiments, the actuation mechanism 3101 is coupled to the adjustable structure 3102 via a lever element 3106. The lever element 3106 can be any elongated structure (e.g., a strut, bar, rod, tube, etc.) configured to transmit a force and/or motion applied by the actuation mechanism 3101 to the adjustable structure 3102. The lever element 3106 can be made of a superelastic material (e.g., nitinol) or another suitable material (e.g., stainless steel, cobalt chromium, a polymer, etc.). Optionally, the lever element 3106 can be made of a non-shape memory material. In other embodiments the lever element 3106 can be made of a shape memory material, but the shape memory properties of the material are not used during operation of the lever element 3106 (e.g., the lever element 3106 is not heated during operation).
In some embodiments, the lever element 3106 includes a first end portion 3108a coupled to the actuation mechanism 3101 and a second end portion 3108b coupled to the adjustable structure 3102. The first end portion 3108a can be pivotally coupled to the actuation mechanism 3101 so that the lever element 3106 can pivot or otherwise rotate relative to the actuation mechanism 3101. The second end portion 3108b can be pivotally coupled to the adjustable structure 3102 so that the lever element 3106 can pivot or otherwise rotate relative to the adjustable structure 3102. The pivotal coupling(s) can be implemented in various ways known to those of skill in the art. For example, the first and/or second end portions 3108a-b can be pivotally coupled using a hinge or other rotational fastener. As another example, the first and/or second end portions 3108a-b can be configured to bend, e.g., by reducing the thickness and/or stiffness of these portions compared to other portions of the lever element 3106.
In some embodiments, the actuation mechanism 3101 is configured to alter the geometry of the adjustable structure 3102 by pivoting the lever element 3106 (e.g., relative to the adjustable structure 3102 and/or the actuation mechanism 3101). For example, pivoting of the lever element 3106 in a first direction D1 can apply an outwardly-directed and/or tensile force against the adjustable structure 3102 to increase the size thereof. Pivoting of the lever element 3106 in a second, opposite direction D2 can apply an inwardly-directed and/or compressive force against the adjustable structure 3102 to decrease the size thereof. In other embodiments pivoting of the lever element 3106 in one direction (e.g., D1 or D2) can release a force that was applied to the adjustable structure 3102 via pivoting of the lever element 3106 in the opposite direction. Additional features of the actuation mechanism 3101 are described in detail below.
The adjustable structure 3102 can be coupled to one or more struts 3110 that connect the adjustable structure 3102 to the shunting element (not shown). The struts 3110 can each be made of a superelastic material (e.g., nitinol) or another suitable material (e.g., stainless steel, cobalt chromium, a polymer, etc.). Each strut can include a first end portion 3112a coupled to the adjustable structure 3102 and second end portion 3112b coupled to the shunting element or to another portion of the system 200. The struts 3110 can be arranged radially around the perimeter (e.g., circumference) of the adjustable structure 3102 in a spoke-like configuration. The struts 3110 can be configured to restrict the extent to which the adjustable structure 3102 can move relative to the shunting element (e.g., along the longitudinal axis of the shunting element). As a result, when the lever element 3106 applies or releases force to the adjustable structure 3102, the adjustable structure 3102 can expand or contract radially in a plane (e.g., a plane including the aperture 3104 or parallel thereto), rather than moving longitudinally (e.g., along the longitudinal axis of the shunting element). In some embodiments, the first and second end portions 3112a-b of each strut 3110 are pivotally coupled to the adjustable structure 3102 and the shunting element, respectively, such that each strut 3110 pivots (e.g., relative to the adjustable structure 3102 and/or shunting element) as the adjustable structure 3102 changes in geometry. The pivotal couplings of the struts 3110 can be implemented as hinges, bendable regions, or any other suitable structure known to those of skill in the art. Although
In some embodiments, the adjustable structure 3102 can be coupled to one or more structural members 3114. The structural members 3114 can be arranged radially around the adjustable structure 3102 in a spoke-like configuration. In the illustrated embodiment, for example, each structural member 3114 is attached to the adjustable structure 3102 at or near a corresponding strut 3110. In other embodiments, some or all of the structural members 3114 can be spaced apart from the struts 3110. The structural members 3114 can be attached to, contact, or otherwise engage the membrane (not shown) to define the shape thereof. In the illustrated embodiment, for example, each structural member 3114 has a curved or bent shape and extends over the struts 3110. As a result, when the membrane is attached to the structural members 3114, the struts 3110 are positioned within the interior space enclosed by the membrane. In some embodiments, the structural members 3114 also extend over the actuation mechanism 3101 and lever element 3106 so that these components are also enclosed within the membrane. Although
Referring to
The actuation mechanism 3101 can include one or more shape memory actuation elements configured to drive the movement of the shuttle element 3116. In the illustrated embodiment, for example, the actuation mechanism 3101 includes a first shape memory actuation element 3118a and a second shape memory actuation element 3118b coupled to the shuttle element 3116. The shuttle element 3116 can be positioned between and coupled to the first and second shape memory actuation elements 3118a-b. In other embodiments one side of the shuttle element 3116 can be mechanically coupled to more than one shape memory actuation element (e.g., both the first and second shape memory actuation elements 3118a-b). Optionally, the first shape memory actuation element 3118a, the second shape memory actuation element 3118b, and the shuttle element 3116 can be located within a housing 320. In such embodiments, the shuttle element 3116 can move (e.g., translate) within the housing 320 to pivot the lever element 3106. In other embodiments the housing 320 can be omitted.
The movement of the shuttle element 3116 can be actuated by the first and second shape memory elements 3118a-b. For example, the first and second shape memory elements 3118a-b can each be configured to change in shape in response to a stimulus, such as heat or mechanical loading. In some embodiments, the first and second shape memory elements 3118a-b are each manufactured or otherwise configured to approach (e.g., change in shape, deform, transform, etc.) a relatively lengthened configuration upon application of heat of sufficient heat to induce at least a temporary change in material state. In other embodiments, the first and second shape memory elements 3118a-b are each manufactured or otherwise configured to approach a relatively shortened configuration upon application of heat. Optionally, one shape memory element can approach a relatively lengthened configuration when sufficiently heated, while the other shape memory element can approach a relatively shortened configuration when sufficiently heated. In some embodiments, at least one shape memory element is manufactured so that, at a first temperature (e.g., body temperature), it is relatively more thermoelastically deformable in response to a fixed force or stress than it would be at a second temperature. The second temperature can be a higher temperature (e.g., a temperature resulting from the application of heat to an element) than the first temperature.
The shape change (e.g., due to deformation by externally-applied forces, due to heating that results in a deformation related to the shape memory effect, etc.) of the first and/or second shape memory elements 3118a-b can actuate movement of the shuttle element 3116 relative to the housing 320. In some embodiments, the first and second shape memory elements 3118a-b, when at an unheated temperature (e.g., at or close to body temperature), are relatively more thermoelastically deformable as described above. In such embodiments, actuation (e.g., expansion/lengthening) of one shape memory element via heating can move shuttle element 3116 in such a way that deforms (e.g., compresses or expands) the other shape memory element.
In a first stage of operation, the first and second shape memory elements 3118a-b can reside in a neutral configuration (e.g., as shown in
In a different stage of operation, the first shape memory actuation element 3118a can change in shape to a relatively shortened configuration and the second shape memory actuation element 3118b can changed in shape to a relatively lengthened configuration. For example, the second shape memory actuation element 3118b can be heated to induce a change in shape to a lengthened configuration (e.g., toward its original manufactured geometric configuration) relative to its shape in the neutral position shown in
In a further stage of operation, the first shape memory actuation element 3118a can change in shape to a relatively lengthened configuration and the second shape memory actuation element 3118b can change in shape to a relatively shortened configuration. For example, the first shape memory actuation element 3118a can be heated to induce a change in shape to a lengthened configuration (e.g., toward its original manufactured geometric configuration) relative to its shape in the neutral position shown in
The actuation mechanism 3101 can be configured in a number of different ways. For example, in some embodiments the first and/or second shape memory actuation elements 3118a-b can be manufactured or otherwise configured to approach a relatively shortened configuration rather than a relatively lengthened configuration when sufficiently heated. Additionally, although
In some embodiments, the first and second shape memory actuation elements 3118a-b are positioned on the same side of the shuttle element 3116. In such embodiments, one shape memory actuation element can be manufactured such that when it is heated it moves towards a relatively lengthened/expanded configuration, and the second shape memory actuation element can be manufactured such that when it is heated it moves towards a relatively shortened/contracted configuration. In other embodiments, any number of shape memory actuation elements that have been manufactured to have similar or dissimilar original geometric configurations may be utilized.
In embodiments of the present technology that utilize heat or another form of energy applied to a shape memory actuation element or another component of the system, the energy/heat can be applied both invasively (e.g., via a catheter delivering laser, radiofrequency, or another form of energy, via an internal stored energy source such as a supercapacitor, etc.), non-invasively (e.g., using radiofrequency energy delivered by a transmitter outside of the body, by focused ultrasound, etc.), or through a combination of these methods.
Although
The system 3200 includes an actuation mechanism 3201 coupled to an adjustable structure 3202. In some embodiments, the adjustable structure 3202 can be operably coupled to a membrane (not shown) and an aperture 3204. The aperture 3204 can at least partially overlap a lumen of a shunting element (not shown) to control fluid flow therethrough, as previously described. Optionally, the adjustable structure 3202 can itself serve as a shunting element defining a lumen for blood flow. In the illustrated embodiment, the adjustable structure 3202 is a stent (e.g., a laser-cut metal stent) positioned at the perimeter of the aperture 3204. The stent can be configured to transform between multiple different geometries (e.g., an expanded configuration, a compressed configuration, and configurations therebetween) when force is applied thereto by the actuation mechanism 3201 and lever element 3206. As shown in
E. Anchors
The anchoring scaffolds 3420 can also define chambers. As illustrated in
The anchoring scaffolds 3420 can be composed of a superelastic material such as nitinol or another suitable material (e.g., an alloy derivative of nitinol, cobalt chromium, stainless steel, etc.). In embodiments in which the anchoring scaffolds 3420 are composed of nitinol, the nitinol has a transition temperature less than body temperature such that the nitinol is in an austenitic material state when implanted, and thus the anchoring scaffolds 3420 are resistant to geometric changes, even if heated.
F. Shunting Assemblies Having Superelastic and Shape Memory Properties
As previously described, in many embodiments described herein the interatrial shunting systems include a nitinol-based actuation element manufactured so as to intentionally utilize the shape-memory properties of the material in vivo rather than the superelastic properties. For example, in some embodiments at least some components utilized will have an austenite finish temperature above body temperature (e.g., above 37 degrees C.). Consequently, the microstructure of these components exists largely in the thermally-induced martensitic material state and/or the R-phase material state throughout assembly, catheterization, deployment, and at least some periods of post-implantation in vivo operation. When deployed from the catheter during a percutaneous delivery to the target organ (e.g., the septal wall of a heart), these components will not generally exhibit self-expanding attributes like traditional superelastic nitinol components. Instead, they may behave similar to a balloon-expandable device (e.g., a cobalt chromium stent) whereby the shape memory component may recover some small amount of elastic recoil when deployed, but the vast majority of the shape change is achieved by applying a force to the component (e.g., a balloon expansion force). However, unlike traditional balloon-expandable devices which achieve this macroscopic shape change via a microstructural non-reversible plastic deformation, the shape memory components achieve their macroscopic shape change via a microstructural reversible thermoelastic deformation. As disclosed above, further deformation of these shape memory elements may be achieved by subsequently applying energy (e.g., heat) to the elements to partially or fully recover the thermoelastic deformation. In some embodiments, an interatrial shunting device may include both nitinol components manufactured to exhibit largely superelastic properties (e.g., anchor elements of the device) and nitinol components manufactured to exhibit largely shape memory properties (e.g., all or portions of actuation elements) at temperature ranges encountered during delivery/deployment and/or post-implantation use.
For example,
The interatrial shunting system 3500 can further include a first plurality of anchors 3512 extending from a first side (e.g., the right atrial side) of the body element 3510 and a second plurality of anchors 3514 extending from an opposing side (e.g., the left atrial side) of the body element 3510. When implanted in the heart, the first plurality of anchors 3512 can engage the septal wall from the right atrial side of the heart and the second plurality of anchors 3514 can engage the septal wall from the left atrial side of the heart. The anchors 3512/3514 can have any suitable shape configured to secure the system 3500 to the septal wall, including, for example a flower petal configuration, a flange configuration, or the like. As illustrated, the first plurality of anchors 3512 can have a different (e.g., larger) size than the second plurality of anchors 3514, although in other configurations the first plurality of anchors 3512 are smaller than or have the same size as the second plurality of anchors 3514.
Referring to
The body element 3510, the first plurality of anchors 3512, and the second plurality of anchors 3514 may be composed of a material (e.g., nitinol) and that has been manufactured such that it exhibits superelastic material properties at and above body temperature. For example, during manufacturing the body element 3510, the first plurality of anchors 3512, and the second plurality of anchors 3514 can be shape set using processes (e.g., high temperatures) that produce a material state transition temperature (e.g., an austenite start temperature, an austenite finish temperature) in these sections of the device that is below body temperature (e.g. below 37 degrees C.). As such, the body element 3510, the first plurality of anchors 3512, and the second plurality of anchors 3514 exhibit superelastic material properties upon implantation into the body. For example, the foregoing sections of the device may be in an austenitic material state while at or above body temperature. Because they are already in an austenitic material state at or above body temperature, applying additional energy (e.g., heat) to the body element 3510, the first plurality of anchors 3512, and the second plurality of anchors 3514 after the system 3500 is implanted in the heart will not change the shape or other dimension of these sections of the device. As a result, the body element 3510, the first plurality of anchors 3512, and the second plurality of anchors 3514 are configured to retain a relatively stable geometry in the heart (e.g., an outer diameter of the body element 3510 does not change, even in response to heat).
Referring to both
A dimension of the lumen 3501 can be adjusted by selectively heating either the first actuation elements 3520 or the second actuation elements 3522, as described in detail previously. For example, heating (e.g., resistively heating) the first actuation elements 3520 above their transition temperature decreases a diameter or other dimension of the lumen 3501, and heating the second actuation elements 3522 above their transition temperature increases a diameter or other dimension of the lumen 3501. However, because the body element 3510 and the anchors 3512, 3514 are partially or entirely in an austenitic material state at body temperature, incidental (or purposeful, as described below) heating of the body element 3510 and/or the anchors 3512, 3514 during actuation of the first actuation elements 3520 and/or the second actuation elements 3522 does not induce a geometry or other dimensional change in the body element 3510 or anchors 3512, 3514. Accordingly, the body element 3510 will maintain a relatively constant outer diameter even during actuation of the first actuation elements 3520 and/or the second actuation elements 3522, and the anchors 3512, 3514 will remain in a desired orientation.
In some embodiments, the first actuation elements 3520 are electrically coupled to and/or integral with the first body element 3510a and/or the first anchors 3520. Because the first body element 3510a and the first anchors 3520 are manufactured such that they are partially or entirely in an austenitic material state at and above body temperature, energy (e.g., an electric current which induces resistive heating) can be applied to any of the foregoing components to help heat, and thereby induce a shape change in, the first actuation elements 3520. For example, heat applied to the first body element 3510a may be passively and/or actively transferred to, and drive actuation of, the first actuation element 3520. Likewise, the second actuation elements 3522 can be electrically coupled to and/or integral with the second body element 3510b and/or the second anchors 3522. Because the second body element 3510b and the second anchors 3522 are also manufactured such that they are partially or entirely in an austenitic material state at and above body temperature, energy can be applied to any of the foregoing components to heat, and thereby induce a shape change in, the second actuation elements 3522. For example, heat applied to the second body element 3510b may be passively and/or actively transferred to, and drive actuation of, the second actuation element 3522. Accordingly, rather than solely applying heat to the actuation elements themselves, heat can be applied to portions of the desired system that surround and/or are in thermal communication with the actuation elements.
G. Operation of Adjustable Interatrial Shunting Systems
Without wishing to be bound by theory, the adjustability of the shunting systems provided herein are expected to advantageously address a number of challenges associated with heart failure treatment. First, heart failure is a heterogenous disease and many patients have various co-morbidities, and the resulting disease presentation can be diverse. Accordingly, a “one size fits all” approach to heart failure treatment will not provide the same therapeutic benefit to each patient. Second, heart failure is a chronic and progress disease. Use of a non-adjustable (i.e., static) device does not permit treatment to be adapted to changes in disease progression. The adjustable shunting systems described herein, however, are expected to advantageously provide increased flexibility to better tailor treatment to a particular patient and/or to various disease stages.
For example, the shunting systems described can enable a clinician to periodically (e.g., monthly, bi-monthly, annually, as needed, etc.) adjust the diameter of a lumen to improve patient treatment. For example, during a patient visit, the clinician can assess a number of patient parameters and determine whether adjusting the geometry and/or size of the lumen, and thus altering blood flow between the LA and the RA, would provide better treatment and/or enhance the patient's quality of life. Patient parameters can include, for example, physiological parameters (e.g., left atrial blood pressure, right atrial blood pressure, the difference between left atrial blood pressure and right atrial blood pressure, flow velocity, heart rate, cardiac output, myocardial strain, etc.), subjective parameters (e.g., whether the patient is fatigued, how the patient feels during exercise, etc.), and other parameters known in the art for assessing whether a treatment is working. If the clinician decides to adjust the diameter of the lumen, the clinician can adjust the device lumen using the techniques described herein.
In some embodiments, the systems described herein can include or be operably coupled to one or more sensors. The sensor(s) can measure one or more physiological parameters related to the system or the environment proximate to the sensor(s), such as left atrial pressure, right atrial pressure, and/or a pressure differential between the LA and RA. The system can adjust the size or geometry of the lumen and/or lumen orifice based on the physiological parameter(s). For example, the sensor(s) can be operably coupled to the actuation assembly such that the actuation assembly adjusts the lumen and/or lumen orifice in response to the sensor data.
Some embodiments of the present technology adjust the relative size and/or shape of the lumen and/or lumen aperture consistently (e.g., continuously, hourly, daily, etc.). Consistent adjustments might be made, for example, to adjust the flow of blood based on a blood pressure level, respiratory rate, heart rate, and/or another parameter of the patient, which changes frequently over the course of a day. For example, the systems described herein can have a baseline state in which the lumen or lumen orifice is substantially closed and does not allow substantial blood flow between the LA and RA, and an active state in which the lumen and lumen orifice are open and allows blood to flow between the LA and RA. The system can transition between the baseline state and the active state whenever one or more patient status parameters change due to exercise, stress, or other factors. In other embodiments, consistent adjustments can be made based on, or in response to, physiological parameters that are detected using sensors, including, for example, sensed left atrial pressure and/or right atrial pressure. If the left atrial pressure increases, the systems can automatically increase a diameter of the lumen and/or lumen orifice to decrease flow resistance between the LA and the RA and allow increased blood flow. In another example, the systems can be configured to adjust based on, or in response to, an input parameter from another device such as a pulmonary arterial pressure sensor, insertable cardiac monitor, pacemaker, defibrillator, cardioverter, wearable, external ECG or PPG, and the like.
Some embodiments of the present technology adjust the relative size and/or shape of the lumen and/or lumen orifice only after a threshold has been reached (e.g., a sufficient period of time has elapsed). This may be done, for example, to avoid unnecessary back and forth adjustments and/or avoid changes based on clinically insignificant changes. In some embodiments, adjustments may occur occasionally as a patient's condition changes. For example, the lumen and/or lumen orifice may gradually open if a patient experiences a sustained rise in left atrial pressure (e.g., rate of change is above a predetermined threshold, and/or the left atrial pressure remains higher than a predetermined threshold for longer than a predetermined amount of time), pulmonary artery pressure, weight, or another physiologically relevant parameters. Additionally or alternatively, adjustments can occur if pressure exceeds a threshold or increases by a threshold amount over a period of time (e.g., several days or more). The diameter of the lumen and/or lumen orifice can then be increased to increase blood flow between the LA and RA and to avoid decompensation.
In some embodiments, the adjustable interatrial shunting systems described herein can include additional or alternative features, such as those described in PCT Patent Application No. PCT/US20/38549, titled ADJUSTABLE INTERATRIAL SHUNTS AND ASSOCIATED SYSTEMS AND METHODS, filed Jun. 18, 2020, the disclosure of which is incorporated by reference herein in its entirety.
Embodiments of the present disclosure may include some or all of the following components: a battery, supercapacitor, or other suitable power source; a microcontroller, FPGA, ASIC, or other programmable component or system capable of storing and executing software and/or firmware that drives operation of an implant; memory such as RAM or ROM to store data and/or software/firmware associated with an implant and/or its operation; wireless communication hardware such as an antenna system configured to transmit via Bluetooth, WiFi, or other protocols known in the art; energy harvesting means, for example a coil or antenna which is capable of receiving and/or reading an externally-provided signal which may be used to power the device, charge a battery, initiate a reading from a sensor, or for other purposes. Embodiments may also include one or more sensors, such as pressure sensors, impedance sensors, accelerometers, force/strain sensors, temperature sensors, flow sensors, optical sensors, cameras, microphones or other acoustic sensors, ultrasonic sensors, ECG or other cardiac rhythm sensors, SpO2 and other sensors adapted to measure tissue and/or blood gas levels, blood volume sensors, and other sensors known to those who are skilled in the art. Embodiments may include portions that are radiopaque and/or ultrasonically reflective to facilitate image-guided implantation or image guided procedures using techniques such as fluoroscopy, ultrasonography, or other imaging methods. Embodiments of the system may include specialized delivery catheters/systems that are adapted to deliver an implant and/or carry out a procedure. Systems may include components such as guidewires, sheaths, dilators, and multiple delivery catheters. Components may be exchanged via over-the-wire, rapid exchange, combination, or other approaches.
The above detailed description of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise forms disclosed above. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology as those skilled in the relevant art will recognize. For example, although steps are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments. For example, although this disclosure has been written to describe devices that are generally described as being used to create a path of fluid communication between the LA and RA, the LV and the right ventricle (RV), or the LA and the coronary sinus, it should be appreciated that similar embodiments could be utilized for shunts between other chambers of heart or for shunts in other regions of the body.
Unless the context clearly requires otherwise, throughout the description and the examples, the words “comprise,” “comprising,” and the like are to be construed in an inclusive sense, as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited to.” As used herein, the terms “connected,” “coupled,” or any variant thereof, means any connection or coupling, either direct or indirect, between two or more elements; the coupling of connection between the elements can be physical, logical, or a combination thereof. Additionally, the words “herein,” “above,” “below,” and words of similar import, when used in this application, shall refer to this application as a whole and not to any particular portions of this application. Where the context permits, words in the above Detailed Description using the singular or plural number may also include the plural or singular number respectively. As used herein, the phrase “and/or” as in “A and/or B” refers to A alone, B alone, and A and B. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with some embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.
This application claims the benefit of the following applications: (a) U.S. Provisional Patent App. No. 62/897,943, filed Sep. 9, 2019;(b) U.S. Provisional Patent App. No. 62/907,696, filed Sep. 29, 2019;(c) U.S. Provisional Patent App. No. 62/907,700, filed Sep. 29, 2019;(d) U.S. Provisional Patent App. No. 62/907,698, filed Sep. 29, 2019;(e) U.S. Provisional Patent App. No. 62/929,608, filed Nov. 1, 2019;(f) U.S. Provisional Patent App. No. 62/959,792, filed Jan. 10, 2020;(g) U.S. Provisional Patent App. No. 62/976,665, filed Feb. 14, 2020;(h) U.S. Provisional Patent App. No. 62/977,933, filed Feb. 18, 2020;(i) U.S. Provisional Patent App. No. 62/994,010, filed Mar. 24, 2020;(j) U.S. Provisional Patent App. No. 63/002,050, filed Mar. 30, 2020;(k) U.S. Provisional Patent App. No. 63/003,594, filed Apr. 1, 2020; and(l) U.S. Provisional Patent App. No. 63/003,632, filed Apr. 1, 2020. All of the foregoing applications are incorporated herein by reference in their entireties. Further, components and features of embodiments disclosed in the applications incorporated by reference may be combined with various components and features disclosed and claimed in the present application.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3874388 | King et al. | Apr 1975 | A |
| 4601309 | Chang | Jul 1986 | A |
| 4662355 | Pieronne et al. | May 1987 | A |
| 4705507 | Boyles | Nov 1987 | A |
| 4836204 | Landymore et al. | Jun 1989 | A |
| 4969890 | Sugita | Nov 1990 | A |
| 4979955 | Smith | Dec 1990 | A |
| 4995857 | Arnold | Feb 1991 | A |
| 5186431 | Tamari | Feb 1993 | A |
| 5197978 | Hess | Mar 1993 | A |
| 5267940 | Moulder | Dec 1993 | A |
| 5290227 | Pasque | Mar 1994 | A |
| 5312341 | Turi | May 1994 | A |
| 5326374 | Ilbawi et al. | Jul 1994 | A |
| 5332402 | Teitelbaum | Jul 1994 | A |
| 5334217 | Das | Aug 1994 | A |
| 5409019 | Wilk | Apr 1995 | A |
| 5429144 | Wilk | Jul 1995 | A |
| 5500015 | Deac | Mar 1996 | A |
| 5531759 | Kensey et al. | Jul 1996 | A |
| 5556386 | Todd | Sep 1996 | A |
| 5584803 | Stevens et al. | Dec 1996 | A |
| 5597377 | Aldea | Jan 1997 | A |
| 5611338 | Gallup | Mar 1997 | A |
| 5645559 | Hachtman et al. | Jul 1997 | A |
| 5655548 | Nelson et al. | Aug 1997 | A |
| 5662711 | Douglas | Sep 1997 | A |
| 5702412 | Popov et al. | Dec 1997 | A |
| 5725552 | Kotula et al. | Mar 1998 | A |
| 5741297 | Simon | Apr 1998 | A |
| 5795307 | Krueger | Aug 1998 | A |
| 5810836 | Hussein et al. | Sep 1998 | A |
| 5824071 | Nelson et al. | Oct 1998 | A |
| 5916193 | Stevens et al. | Jun 1999 | A |
| 5941850 | Shah et al. | Aug 1999 | A |
| 5944019 | Kundson et al. | Aug 1999 | A |
| 5957949 | Leonhardt et al. | Sep 1999 | A |
| 6024743 | Edwards | Feb 2000 | A |
| 6039759 | Carpentier et al. | Mar 2000 | A |
| 6077298 | Tu et al. | Jun 2000 | A |
| 6120534 | Ruiz | Sep 2000 | A |
| 6126686 | Badylak et al. | Oct 2000 | A |
| 6165188 | Saadat et al. | Dec 2000 | A |
| 6165209 | Patterson et al. | Dec 2000 | A |
| 6210318 | Lederman | Apr 2001 | B1 |
| 6217541 | Yu | Apr 2001 | B1 |
| 6240322 | Peterfeso et al. | May 2001 | B1 |
| 6242762 | Brown et al. | Jun 2001 | B1 |
| 6254564 | Wilk et al. | Jul 2001 | B1 |
| 6260552 | Mortier et al. | Jul 2001 | B1 |
| 6270526 | Cox | Aug 2001 | B1 |
| 6277078 | Porat et al. | Aug 2001 | B1 |
| 6302892 | Wilk | Oct 2001 | B1 |
| 6328699 | Eigler et al. | Dec 2001 | B1 |
| 6344022 | Jarvik | Feb 2002 | B1 |
| 6358277 | Duran | Mar 2002 | B1 |
| 6406422 | Landesberg | Jun 2002 | B1 |
| 6447539 | Nelson et al. | Sep 2002 | B1 |
| 6451051 | Drasler et al. | Sep 2002 | B2 |
| 6458153 | Bailey et al. | Oct 2002 | B1 |
| 6468303 | Amplatz et al. | Oct 2002 | B1 |
| 6478776 | Rosenman et al. | Nov 2002 | B1 |
| 6491705 | Gifford, III et al. | Dec 2002 | B2 |
| 6514285 | Pinchasik | Feb 2003 | B1 |
| 6527698 | Kung et al. | Mar 2003 | B1 |
| 6544208 | Ethier et al. | Apr 2003 | B2 |
| 6562066 | Martin | May 2003 | B1 |
| 6572652 | Shaknovich | Jun 2003 | B2 |
| 6589198 | Soltanpour et al. | Jul 2003 | B1 |
| 6632169 | Korakianitis et al. | Oct 2003 | B2 |
| 6638303 | Campbell | Oct 2003 | B1 |
| 6641610 | Wolf et al. | Nov 2003 | B2 |
| 6652578 | Bailey et al. | Nov 2003 | B2 |
| 6685664 | Levin et al. | Feb 2004 | B2 |
| 6712836 | Berg et al. | Mar 2004 | B1 |
| 6783499 | Schwartz | Aug 2004 | B2 |
| 6909920 | Lokhoff et al. | Jun 2005 | B2 |
| 6911043 | Myers et al. | Jun 2005 | B2 |
| 6926670 | Rich et al. | Aug 2005 | B2 |
| 7001409 | Amplatz | Feb 2006 | B2 |
| 7011095 | Wolf et al. | Mar 2006 | B2 |
| 7056294 | Khairkhahan et al. | Jun 2006 | B2 |
| 7149587 | Wardle et al. | Dec 2006 | B2 |
| 7175656 | Khairkhahan | Feb 2007 | B2 |
| 7270675 | Chun et al. | Sep 2007 | B2 |
| 7294115 | Wilk | Nov 2007 | B1 |
| 7311690 | Burnett | Dec 2007 | B2 |
| 7311730 | Gabbay | Dec 2007 | B2 |
| 7317951 | Schneider et al. | Jan 2008 | B2 |
| 7389134 | Karicherla et al. | Jun 2008 | B1 |
| 7390310 | McCusker et al. | Jun 2008 | B2 |
| 7513908 | Lattouf | Apr 2009 | B2 |
| 7524329 | Rucker | Apr 2009 | B2 |
| 7524330 | Berreklouw | Apr 2009 | B2 |
| 7524332 | Osborne et al. | Apr 2009 | B2 |
| 7608067 | Bonni | Oct 2009 | B2 |
| 7617001 | Penner et al. | Nov 2009 | B2 |
| 7634318 | Tran et al. | Dec 2009 | B2 |
| 7658747 | Forde et al. | Feb 2010 | B2 |
| 7699059 | Fonseca et al. | Apr 2010 | B2 |
| 7736327 | Wilk et al. | Jun 2010 | B2 |
| 7780725 | Haug et al. | Aug 2010 | B2 |
| 7794473 | Tessmer et al. | Sep 2010 | B2 |
| 7806921 | Hoffman | Oct 2010 | B2 |
| 7860579 | Goetzinger et al. | Dec 2010 | B2 |
| 7892246 | Akin et al. | Feb 2011 | B2 |
| 7905901 | Corcoran et al. | Mar 2011 | B2 |
| 7922764 | Gordy et al. | Apr 2011 | B2 |
| 7938840 | Golden et al. | May 2011 | B2 |
| 7967769 | Faul et al. | Jun 2011 | B2 |
| 7988724 | Salahieh et al. | Aug 2011 | B2 |
| 8012198 | Hill et al. | Sep 2011 | B2 |
| 8016877 | Seguin et al. | Sep 2011 | B2 |
| 8043360 | McNamara et al. | Oct 2011 | B2 |
| 8070708 | Rottenberg et al. | Dec 2011 | B2 |
| 8091556 | Keren et al. | Jan 2012 | B2 |
| 8096959 | Stewart et al. | Jan 2012 | B2 |
| 8147545 | Avior | Apr 2012 | B2 |
| 8157860 | McNamara et al. | Apr 2012 | B2 |
| 8172896 | McNamara et al. | May 2012 | B2 |
| 8235916 | Whiting et al. | Aug 2012 | B2 |
| 8235933 | Keren et al. | Aug 2012 | B2 |
| 8246677 | Ryan | Aug 2012 | B2 |
| 8252042 | McNamara et al. | Aug 2012 | B2 |
| 8303511 | Eigler et al. | Nov 2012 | B2 |
| 8328751 | Keren et al. | Dec 2012 | B2 |
| 8348996 | Tuval et al. | Jan 2013 | B2 |
| 8398708 | Meiri et al. | Mar 2013 | B2 |
| 8460366 | Rowe | Jun 2013 | B2 |
| 8460372 | McNamara et al. | Jun 2013 | B2 |
| 8597225 | Kapadia | Dec 2013 | B2 |
| 8647381 | Essinger et al. | Feb 2014 | B2 |
| 8696611 | Nitzan et al. | Apr 2014 | B2 |
| 8740962 | Finch et al. | Jun 2014 | B2 |
| 8745845 | Finch et al. | Jun 2014 | B2 |
| 8747458 | Tuval et al. | Jun 2014 | B2 |
| 8752258 | Finch et al. | Jun 2014 | B2 |
| 8764848 | Callaghan et al. | Jul 2014 | B2 |
| 8882697 | Celermajer et al. | Nov 2014 | B2 |
| 8951223 | McNamara et al. | Feb 2015 | B2 |
| 9005155 | Sugimoto | Apr 2015 | B2 |
| 9034034 | Nitzan et al. | May 2015 | B2 |
| 9138213 | Amin et al. | Sep 2015 | B2 |
| 9204842 | Mothilal et al. | Dec 2015 | B2 |
| 9205236 | McNamara et al. | Dec 2015 | B2 |
| 9232997 | Sugimoto et al. | Jan 2016 | B2 |
| 9277995 | Celermajer et al. | Mar 2016 | B2 |
| 9358371 | McNamara et al. | Jun 2016 | B2 |
| 9456812 | Finch et al. | Oct 2016 | B2 |
| 9610041 | Foster et al. | Apr 2017 | B2 |
| 9629715 | Nitzan et al. | Apr 2017 | B2 |
| 9642993 | McNamara et al. | May 2017 | B2 |
| 9649480 | Sugimoto et al. | May 2017 | B2 |
| 9681948 | Levi et al. | Jun 2017 | B2 |
| 9707382 | Nitzan et al. | Jul 2017 | B2 |
| 9713696 | Yacoby et al. | Jul 2017 | B2 |
| 9724499 | Rottenberg et al. | Aug 2017 | B2 |
| 9757107 | McNamara et al. | Sep 2017 | B2 |
| 9775636 | Fazio et al. | Oct 2017 | B2 |
| 9918856 | Favier et al. | Mar 2018 | B2 |
| 9937036 | Sugimoto et al. | Apr 2018 | B2 |
| 9943670 | Keren et al. | Apr 2018 | B2 |
| 9980815 | Nitzan et al. | May 2018 | B2 |
| 10045766 | McNamara et al. | Aug 2018 | B2 |
| 10076403 | Eigler et al. | Sep 2018 | B1 |
| 10188375 | McNamara et al. | Jan 2019 | B2 |
| 10207087 | Keren | Feb 2019 | B2 |
| 10251740 | Eigler et al. | Apr 2019 | B2 |
| 10292690 | Celermajer et al. | May 2019 | B2 |
| 10350384 | Farnan et al. | Jul 2019 | B2 |
| 10357357 | Levi et al. | Jul 2019 | B2 |
| 10368981 | Nitzan et al. | Aug 2019 | B2 |
| 10376359 | Essinger et al. | Aug 2019 | B2 |
| 10376680 | McNamara et al. | Aug 2019 | B2 |
| 10398421 | Celermajer | Sep 2019 | B2 |
| 10405903 | Biesinger et al. | Sep 2019 | B1 |
| 10413284 | McNamara et al. | Sep 2019 | B2 |
| 10413286 | McNamara et al. | Sep 2019 | B2 |
| 10463477 | Forcucci et al. | Nov 2019 | B2 |
| 10463490 | Rottenberg et al. | Nov 2019 | B2 |
| 10471251 | Manicka | Nov 2019 | B1 |
| 10478594 | Yacoby et al. | Nov 2019 | B2 |
| 10568751 | McNamara | Feb 2020 | B2 |
| 10588611 | Magnin et al. | Mar 2020 | B2 |
| 10610210 | Finch et al. | Apr 2020 | B2 |
| 10624621 | Celermajer | Apr 2020 | B2 |
| 10632292 | Forcucci et al. | Apr 2020 | B2 |
| 10639459 | Nitzan et al. | May 2020 | B2 |
| 10667896 | Delaney, Jr. et al. | Jun 2020 | B2 |
| 10675450 | Finch | Jun 2020 | B2 |
| 10828151 | Nitzan et al. | Nov 2020 | B2 |
| 10835394 | Nae et al. | Nov 2020 | B2 |
| 10898698 | Eigler et al. | Jan 2021 | B1 |
| 10912645 | Rottenberg et al. | Feb 2021 | B2 |
| 10925706 | Eigler et al. | Feb 2021 | B2 |
| 10932786 | McNamara et al. | Mar 2021 | B2 |
| 10940296 | Keren | Mar 2021 | B2 |
| 10945716 | Chen et al. | Mar 2021 | B2 |
| 11135410 | Finch et al. | Oct 2021 | B2 |
| 11160961 | Fahey et al. | Nov 2021 | B2 |
| 11253685 | Fahey et al. | Feb 2022 | B2 |
| 11622695 | Andriola et al. | Apr 2023 | B1 |
| 11633194 | Alexander et al. | Apr 2023 | B2 |
| 11801369 | Fahey et al. | Oct 2023 | B2 |
| 20020072656 | Vantassel et al. | Jun 2002 | A1 |
| 20020115991 | Edwards | Aug 2002 | A1 |
| 20020142119 | Seward et al. | Oct 2002 | A1 |
| 20020161427 | Rabkin et al. | Oct 2002 | A1 |
| 20020169371 | Gilderdale | Nov 2002 | A1 |
| 20020169475 | Gainor et al. | Nov 2002 | A1 |
| 20020177891 | Miles et al. | Nov 2002 | A1 |
| 20030125798 | Martin | Jul 2003 | A1 |
| 20030127090 | Gifford et al. | Jul 2003 | A1 |
| 20030163190 | LaFont et al. | Aug 2003 | A1 |
| 20040016514 | Nien | Jan 2004 | A1 |
| 20040077988 | Tweden et al. | Apr 2004 | A1 |
| 20040088045 | Cox | May 2004 | A1 |
| 20040093075 | Kuehne | May 2004 | A1 |
| 20040143294 | Corcoran et al. | Jul 2004 | A1 |
| 20040147869 | Wolf et al. | Jul 2004 | A1 |
| 20040147939 | Rabkin et al. | Jul 2004 | A1 |
| 20040158143 | Flaherty et al. | Aug 2004 | A1 |
| 20040162514 | Alferness et al. | Aug 2004 | A1 |
| 20040186566 | Hindrichs et al. | Sep 2004 | A1 |
| 20040210190 | Kohler et al. | Oct 2004 | A1 |
| 20040215067 | Stiger et al. | Oct 2004 | A1 |
| 20040215323 | Stiger | Oct 2004 | A1 |
| 20050004641 | Pappu | Jan 2005 | A1 |
| 20050033351 | Newton | Feb 2005 | A1 |
| 20050060030 | Lashinski et al. | Mar 2005 | A1 |
| 20050101946 | Govari et al. | May 2005 | A1 |
| 20050148925 | Rottenberg et al. | Jul 2005 | A1 |
| 20050159789 | Brockway et al. | Jul 2005 | A1 |
| 20050165344 | Dobak, III | Jul 2005 | A1 |
| 20050192627 | Whisenant et al. | Sep 2005 | A1 |
| 20050204811 | Neff | Sep 2005 | A1 |
| 20050251212 | Kieval et al. | Nov 2005 | A1 |
| 20050288722 | Eigler et al. | Dec 2005 | A1 |
| 20060009810 | Mann et al. | Jan 2006 | A1 |
| 20060025857 | Bergheim et al. | Feb 2006 | A1 |
| 20060047205 | Ludomirsky et al. | Mar 2006 | A1 |
| 20060064135 | Brockway | Mar 2006 | A1 |
| 20060111660 | Wolf et al. | May 2006 | A1 |
| 20060116625 | Renati et al. | Jun 2006 | A1 |
| 20060200030 | White et al. | Sep 2006 | A1 |
| 20070010837 | Tanaka | Jan 2007 | A1 |
| 20070010852 | Blaeser et al. | Jan 2007 | A1 |
| 20070043435 | Seguin et al. | Feb 2007 | A1 |
| 20070088220 | Stahmann | Apr 2007 | A1 |
| 20070088223 | Mann et al. | Apr 2007 | A1 |
| 20070112344 | Keilman | May 2007 | A1 |
| 20070118039 | Bodecker et al. | May 2007 | A1 |
| 20070150019 | Youker et al. | Jun 2007 | A1 |
| 20070213813 | Von Segesser et al. | Sep 2007 | A1 |
| 20070282157 | Rottenberg et al. | Dec 2007 | A1 |
| 20080097276 | Bertrand et al. | Apr 2008 | A1 |
| 20080108904 | Heil | May 2008 | A1 |
| 20080119891 | Miles et al. | May 2008 | A1 |
| 20080127689 | McCusker et al. | Jun 2008 | A1 |
| 20080171941 | Huelskamp et al. | Jul 2008 | A1 |
| 20080208083 | Lin et al. | Aug 2008 | A1 |
| 20080208286 | Kieval et al. | Aug 2008 | A1 |
| 20090025459 | Zhang et al. | Jan 2009 | A1 |
| 20090036975 | Ward et al. | Feb 2009 | A1 |
| 20090243956 | Keilman et al. | Oct 2009 | A1 |
| 20090270742 | Wolinsky et al. | Oct 2009 | A1 |
| 20090276040 | Rowe et al. | Nov 2009 | A1 |
| 20090281557 | Sander | Nov 2009 | A1 |
| 20100063375 | Kassab et al. | Mar 2010 | A1 |
| 20100076366 | Henderson, Sr. et al. | Mar 2010 | A1 |
| 20100076517 | Imran | Mar 2010 | A1 |
| 20100106028 | Penner et al. | Apr 2010 | A1 |
| 20100160906 | Jarrard | Jun 2010 | A1 |
| 20100168672 | Carr | Jul 2010 | A1 |
| 20100179449 | Chow et al. | Jul 2010 | A1 |
| 20100241241 | McKnight et al. | Sep 2010 | A1 |
| 20100249560 | Levinson et al. | Sep 2010 | A1 |
| 20100275592 | Topliss et al. | Nov 2010 | A1 |
| 20100298930 | Orlov | Nov 2010 | A1 |
| 20110054515 | Bridgeman et al. | Mar 2011 | A1 |
| 20110082377 | Ah | Apr 2011 | A1 |
| 20110218480 | Rottenberg et al. | Sep 2011 | A1 |
| 20110218481 | Rottenberg et al. | Sep 2011 | A1 |
| 20110257723 | McNamara | Oct 2011 | A1 |
| 20110264194 | Griswold | Oct 2011 | A1 |
| 20110282217 | Nashet | Nov 2011 | A1 |
| 20110295183 | Finch et al. | Dec 2011 | A1 |
| 20120053686 | McNamara et al. | Mar 2012 | A1 |
| 20120059431 | Williams et al. | Mar 2012 | A1 |
| 20120229272 | Jacob et al. | Sep 2012 | A1 |
| 20120265296 | McNamara et al. | Oct 2012 | A1 |
| 20120283773 | Van Tassel et al. | Nov 2012 | A1 |
| 20120290062 | McNamara et al. | Nov 2012 | A1 |
| 20130085350 | Schugt et al. | Apr 2013 | A1 |
| 20130123569 | Gross | May 2013 | A1 |
| 20130144379 | Najafi et al. | Jun 2013 | A1 |
| 20130178783 | McNamara et al. | Jul 2013 | A1 |
| 20130178784 | McNamara et al. | Jul 2013 | A1 |
| 20130190799 | Clark | Jul 2013 | A1 |
| 20130192611 | Taepke, II et al. | Aug 2013 | A1 |
| 20130197423 | Keren et al. | Aug 2013 | A1 |
| 20130211221 | Sunnarborg et al. | Aug 2013 | A1 |
| 20130253343 | Waldhauser et al. | Sep 2013 | A1 |
| 20130261531 | Gallagher et al. | Oct 2013 | A1 |
| 20130293025 | Xu et al. | Nov 2013 | A1 |
| 20140012342 | Penner et al. | Jan 2014 | A1 |
| 20140046427 | Michalak | Feb 2014 | A1 |
| 20140121750 | Hadley et al. | May 2014 | A1 |
| 20140128795 | Karen et al. | May 2014 | A1 |
| 20140128796 | Keren et al. | May 2014 | A1 |
| 20140163449 | Rottenberg et al. | Jun 2014 | A1 |
| 20140213915 | Doan et al. | Jul 2014 | A1 |
| 20140213959 | Nitzan et al. | Jul 2014 | A1 |
| 20140222040 | Park et al. | Aug 2014 | A1 |
| 20140222144 | Eberhardt et al. | Aug 2014 | A1 |
| 20140249616 | Strauss | Sep 2014 | A1 |
| 20140277054 | McNamara et al. | Sep 2014 | A1 |
| 20150034217 | Vad | Feb 2015 | A1 |
| 20150039084 | Levi et al. | Feb 2015 | A1 |
| 20150084585 | Moran | Mar 2015 | A1 |
| 20150119796 | Finch | Apr 2015 | A1 |
| 20150148731 | McNamara et al. | May 2015 | A1 |
| 20150157268 | Winshtein et al. | Jun 2015 | A1 |
| 20150208929 | Rowland et al. | Jul 2015 | A1 |
| 20150223707 | Ludoph | Aug 2015 | A1 |
| 20150230843 | Palmer et al. | Aug 2015 | A1 |
| 20150231387 | Harding et al. | Aug 2015 | A1 |
| 20150287544 | Irazoqui et al. | Oct 2015 | A1 |
| 20160022423 | Mcnamara et al. | Jan 2016 | A1 |
| 20160089079 | Stein | Mar 2016 | A1 |
| 20160151179 | Favier et al. | Jun 2016 | A1 |
| 20160158561 | Reddy | Jun 2016 | A1 |
| 20160220357 | Anand et al. | Aug 2016 | A1 |
| 20160235999 | Nuta et al. | Aug 2016 | A1 |
| 20160302808 | Loganathan et al. | Oct 2016 | A1 |
| 20170014067 | Peppou et al. | Jan 2017 | A1 |
| 20170105635 | Cho et al. | Apr 2017 | A1 |
| 20170113026 | Finch | Apr 2017 | A1 |
| 20170312078 | Krivoruchko | Nov 2017 | A1 |
| 20170340460 | Rosen et al. | Nov 2017 | A1 |
| 20180014828 | Fonte et al. | Jan 2018 | A1 |
| 20180117341 | Kane et al. | May 2018 | A1 |
| 20180168463 | Morris et al. | Jun 2018 | A1 |
| 20180250014 | Melanson et al. | Sep 2018 | A1 |
| 20180256865 | Finch et al. | Sep 2018 | A1 |
| 20180262037 | Meskeus | Sep 2018 | A1 |
| 20180296375 | Van Langenhove | Oct 2018 | A1 |
| 20180310839 | McCaffrey et al. | Nov 2018 | A1 |
| 20190000327 | Doan et al. | Jan 2019 | A1 |
| 20190014993 | Kaiser | Jan 2019 | A1 |
| 20190015103 | Sharma | Jan 2019 | A1 |
| 20190021861 | Finch | Jan 2019 | A1 |
| 20190150758 | Bailey et al. | May 2019 | A1 |
| 20190167197 | Abuuassar et al. | Jun 2019 | A1 |
| 20190175883 | Wessler et al. | Jun 2019 | A1 |
| 20190192864 | Koop et al. | Jun 2019 | A1 |
| 20190254814 | Nitzan et al. | Aug 2019 | A1 |
| 20190262118 | Elgler et al. | Aug 2019 | A1 |
| 20190269392 | Celermajer et al. | Sep 2019 | A1 |
| 20190274855 | Pate et al. | Sep 2019 | A1 |
| 20190298556 | Bohn et al. | Oct 2019 | A1 |
| 20190307459 | Celermajer et al. | Oct 2019 | A1 |
| 20190328513 | Levi et al. | Oct 2019 | A1 |
| 20190336135 | Inouye et al. | Nov 2019 | A1 |
| 20190336163 | McNamara et al. | Nov 2019 | A1 |
| 20190350519 | Bailey et al. | Nov 2019 | A1 |
| 20200008870 | Gruba et al. | Jan 2020 | A1 |
| 20200060825 | Rottenberg et al. | Feb 2020 | A1 |
| 20200078196 | Rosen et al. | Mar 2020 | A1 |
| 20200078558 | Yacoby et al. | Mar 2020 | A1 |
| 20200085600 | Schwartz et al. | Mar 2020 | A1 |
| 20200188143 | McNamara | Jun 2020 | A1 |
| 20200196867 | Andersen et al. | Jun 2020 | A1 |
| 20200196876 | Minor et al. | Jun 2020 | A1 |
| 20200197178 | Vecchio | Jun 2020 | A1 |
| 20200229977 | Mixter et al. | Jul 2020 | A1 |
| 20200229981 | Mixter et al. | Jul 2020 | A1 |
| 20200229982 | Mixter et al. | Jul 2020 | A1 |
| 20200245991 | Celermajer | Aug 2020 | A1 |
| 20200253615 | Melanson et al. | Aug 2020 | A1 |
| 20200260991 | Rowlaud et al. | Aug 2020 | A1 |
| 20200261705 | Nitzan et al. | Aug 2020 | A1 |
| 20200268515 | Vettukattil et al. | Aug 2020 | A1 |
| 20200281611 | Kelly et al. | Sep 2020 | A1 |
| 20200315599 | Nae et al. | Oct 2020 | A1 |
| 20200368505 | Nae et al. | Nov 2020 | A1 |
| 20200391016 | Passman et al. | Dec 2020 | A1 |
| 20210030273 | Huang et al. | Feb 2021 | A1 |
| 20210038230 | Larsen et al. | Feb 2021 | A1 |
| 20210052378 | Nitzan et al. | Feb 2021 | A1 |
| 20210059527 | Najafi | Mar 2021 | A1 |
| 20210085935 | Fahey et al. | Mar 2021 | A1 |
| 20210100513 | Sahmauyar et al. | Apr 2021 | A1 |
| 20210100665 | Nae et al. | Apr 2021 | A1 |
| 20210121179 | Ben-david et al. | Apr 2021 | A1 |
| 20210145331 | Simpson et al. | May 2021 | A1 |
| 20210153776 | Minar et al. | May 2021 | A1 |
| 20210177508 | Kellerman | Jun 2021 | A1 |
| 20210205590 | Fahey et al. | Jul 2021 | A1 |
| 20210212638 | Golda et al. | Jul 2021 | A1 |
| 20210259732 | Dicicco et al. | Aug 2021 | A1 |
| 20210259829 | Quinn | Aug 2021 | A1 |
| 20210259839 | Cole et al. | Aug 2021 | A1 |
| 20210290214 | Cole et al. | Sep 2021 | A1 |
| 20210290356 | Brinkmann | Sep 2021 | A1 |
| 20210298763 | Stahmann et al. | Sep 2021 | A1 |
| 20210299425 | Kume et al. | Sep 2021 | A1 |
| 20210299430 | Ratz et al. | Sep 2021 | A1 |
| 20210361238 | Bak-Boychuk et al. | Nov 2021 | A1 |
| 20210361257 | Eimer et al. | Nov 2021 | A1 |
| 20210370032 | Fahey et al. | Dec 2021 | A1 |
| 20210401418 | Dang et al. | Dec 2021 | A1 |
| 20220008014 | Rowe et al. | Jan 2022 | A1 |
| 20220039670 | Berrada et al. | Feb 2022 | A1 |
| 20220039671 | Fahey | Feb 2022 | A1 |
| 20220117555 | Zarbatauy et al. | Apr 2022 | A1 |
| 20220118228 | Fahey et al. | Apr 2022 | A1 |
| 20220142652 | Alexander et al. | May 2022 | A1 |
| 20220143368 | Pulugurtha et al. | May 2022 | A1 |
| 20220151618 | Eigler et al. | May 2022 | A1 |
| 20220167861 | Stahmann | Jun 2022 | A1 |
| 20220184355 | Fahey et al. | Jun 2022 | A1 |
| 20220192677 | Wedul et al. | Jun 2022 | A1 |
| 20220218355 | Wedul et al. | Jul 2022 | A1 |
| 20220226000 | Alexander et al. | Jul 2022 | A1 |
| 20220226623 | Fahey et al. | Jul 2022 | A1 |
| 20220240856 | Stahmann et al. | Aug 2022 | A1 |
| 20220265280 | Chamorro et al. | Aug 2022 | A1 |
| 20220313426 | Gifford, III et al. | Oct 2022 | A1 |
| 20230056924 | Fox et al. | Feb 2023 | A1 |
| 20230084193 | Fahey et al. | Mar 2023 | A1 |
| 20230118243 | Fox et al. | Apr 2023 | A1 |
| 20230129883 | Andriola et al. | Apr 2023 | A1 |
| 20230165672 | Fahey et al. | Jun 2023 | A1 |
| 20230191094 | Fahey et al. | Jun 2023 | A1 |
| 20230201545 | Alexander et al. | Jun 2023 | A1 |
| 20230201546 | Fahey et al. | Jun 2023 | A1 |
| 20230240852 | Fahey et al. | Aug 2023 | A1 |
| 20240165381 | Fahey et al. | May 2024 | A1 |
| 20240225661 | Alexander et al. | Jul 2024 | A9 |
| Number | Date | Country |
|---|---|---|
| 2005211243 | Aug 2005 | AU |
| 2010344182 | Aug 2012 | AU |
| 2011332324 | Jun 2013 | AU |
| 2012214279 | Aug 2013 | AU |
| 2018228451 | Sep 2019 | AU |
| 2785041 | Aug 2011 | CA |
| 2786575 | Aug 2011 | CA |
| 2818417 | May 2012 | CA |
| 2955389 | Jan 2016 | CA |
| 3054891 | Sep 2018 | CA |
| 101415452 | Apr 2009 | CN |
| 102458316 | May 2012 | CN |
| 102905626 | Jan 2013 | CN |
| 103458832 | Dec 2013 | CN |
| 105662653 | Jun 2016 | CN |
| 106456308 | Feb 2017 | CN |
| 109646063 | Apr 2019 | CN |
| 110536657 | Dec 2019 | CN |
| 1547549 | Jun 2005 | EP |
| 1112044 | Jan 2007 | EP |
| 2097012 | Sep 2009 | EP |
| 2528646 | Dec 2012 | EP |
| 2642954 | Oct 2013 | EP |
| 2967867 | Jan 2016 | EP |
| 3087953 | Nov 2016 | EP |
| 3291773 | Mar 2018 | EP |
| 3300672 | Apr 2018 | EP |
| 3329860 | Jun 2018 | EP |
| 3579907 | Dec 2019 | EP |
| 3589238 | Jan 2020 | EP |
| 3624701 | Mar 2020 | EP |
| 2999412 | May 2020 | EP |
| 3705154 | Sep 2020 | EP |
| 3716877 | Oct 2020 | EP |
| 3740163 | Nov 2020 | EP |
| 3766431 | Jan 2021 | EP |
| 3834737 | Jun 2021 | EP |
| 3843618 | Jul 2021 | EP |
| 3871626 | Sep 2021 | EP |
| 3886761 | Oct 2021 | EP |
| 3893731 | Oct 2021 | EP |
| 3897369 | Oct 2021 | EP |
| 176973 | Dec 2006 | IL |
| 221127 | Sep 2012 | IL |
| 226374 | Jul 2013 | IL |
| 215975 | Nov 2016 | IL |
| 227756 | Jun 2017 | IL |
| 220201 | Aug 2017 | IL |
| 253648 | Sep 2017 | IL |
| 255379 | Dec 2017 | IL |
| 252395 | Apr 2020 | IL |
| 2011KN04472 | Jul 2012 | IN |
| 2012KN01275 | Feb 2013 | IN |
| 2013KN01954 | Nov 2013 | IN |
| 2013CN06525 | Aug 2014 | IN |
| 2012KN01988 | Aug 2016 | IN |
| 2005177491 | Jul 2005 | JP |
| 2007527742 | Oct 2007 | JP |
| 2008504878 | Feb 2008 | JP |
| 2010508093 | Mar 2010 | JP |
| 2012196504 | Oct 2012 | JP |
| 2013046784 | Mar 2013 | JP |
| 2014503246 | Feb 2014 | JP |
| 2014512869 | May 2014 | JP |
| 2017508581 | Mar 2017 | JP |
| 2020509812 | Apr 2020 | JP |
| 20010046155 | Jun 2001 | KR |
| WO99029227 | Jun 1999 | WO |
| WO2003028522 | Apr 2003 | WO |
| WO2005074367 | Aug 2005 | WO |
| WO2006012038 | Feb 2006 | WO |
| WO2006089236 | Aug 2006 | WO |
| WO2007083288 | Jul 2007 | WO |
| WO2008055301 | May 2008 | WO |
| WO2010128501 | Nov 2010 | WO |
| WO2010129089 | Nov 2010 | WO |
| WO2011093941 | Aug 2011 | WO |
| WO2011094521 | Aug 2011 | WO |
| WO2012071075 | May 2012 | WO |
| WO2012085913 | Jun 2012 | WO |
| WO2012109557 | Aug 2012 | WO |
| WO2013014539 | Jan 2013 | WO |
| WO2013096965 | Jun 2013 | WO |
| WO2014091222 | Jun 2014 | WO |
| WO2014150106 | Sep 2014 | WO |
| WO2014188279 | Nov 2014 | WO |
| WO2015135955 | Sep 2015 | WO |
| WO2016014821 | Jan 2016 | WO |
| WO2016038115 | Mar 2016 | WO |
| WO2016178171 | Nov 2016 | WO |
| WO2017151566 | Sep 2017 | WO |
| WO2018024868 | Feb 2018 | WO |
| WO2018132549 | Jul 2018 | WO |
| WO2018158747 | Sep 2018 | WO |
| WO2019186101 | Feb 2019 | WO |
| WO 2019142152 | Jul 2019 | WO |
| WO2019175401 | Sep 2019 | WO |
| WO2019179447 | Sep 2019 | WO |
| WO2019188917 | Oct 2019 | WO |
| WO2019189079 | Oct 2019 | WO |
| WO2019209420 | Oct 2019 | WO |
| WO2020023514 | Jan 2020 | WO |
| WO2020094085 | May 2020 | WO |
| WO2020094087 | May 2020 | WO |
| WO2020094094 | May 2020 | WO |
| WO2020110048 | Jun 2020 | WO |
| WO2020123338 | Jun 2020 | WO |
| WO2020132678 | Jun 2020 | WO |
| WO2020142515 | Jul 2020 | WO |
| WO2020142613 | Jul 2020 | WO |
| WO2020198694 | Oct 2020 | WO |
| WO2020202046 | Oct 2020 | WO |
| WO2020206366 | Oct 2020 | WO |
| WO2020215090 | Oct 2020 | WO |
| WO2020217194 | Oct 2020 | WO |
| WO2020219265 | Oct 2020 | WO |
| WO2020225698 | Nov 2020 | WO |
| WO2020225757 | Nov 2020 | WO |
| WO2020229636 | Nov 2020 | WO |
| WO2020234751 | Nov 2020 | WO |
| WO2020251700 | Dec 2020 | WO |
| WO2020259492 | Dec 2020 | WO |
| WO2021025905 | Feb 2021 | WO |
| WO2021026485 | Feb 2021 | WO |
| WO202104653 | Mar 2021 | WO |
| WO2021050589 | Mar 2021 | WO |
| WO2021055264 | Mar 2021 | WO |
| WO2021065873 | Apr 2021 | WO |
| WO2021065874 | Apr 2021 | WO |
| WO2021065875 | Apr 2021 | WO |
| WO2021065912 | Apr 2021 | WO |
| WO2021072315 | Apr 2021 | WO |
| WO2021086707 | May 2021 | WO |
| WO2021091566 | May 2021 | WO |
| WO2021096766 | May 2021 | WO |
| WO2021101707 | May 2021 | WO |
| WO2021113670 | Jun 2021 | WO |
| WO2021126699 | Jun 2021 | WO |
| WO2021136252 | Jul 2021 | WO |
| WO2021136261 | Jul 2021 | WO |
| WO2021138041 | Jul 2021 | WO |
| WO2021146342 | Jul 2021 | WO |
| WO2021150765 | Jul 2021 | WO |
| WO2021158559 | Aug 2021 | WO |
| WO2021159001 | Aug 2021 | WO |
| WO2021162888 | Aug 2021 | WO |
| WO2021178636 | Sep 2021 | WO |
| WO2021190547 | Sep 2021 | WO |
| WO2021212011 | Oct 2021 | WO |
| WO2021216964 | Oct 2021 | WO |
| WO2021217055 | Oct 2021 | WO |
| WO2021217059 | Oct 2021 | WO |
| WO2021224736 | Nov 2021 | WO |
| WO2022046921 | Mar 2022 | WO |
| WO2022076601 | Apr 2022 | WO |
| WO2022081980 | Apr 2022 | WO |
| WO2022103973 | May 2022 | WO |
| WO2022192280 | Sep 2022 | WO |
| WO2022266465 | Dec 2022 | WO |
| WO2022266503 | Dec 2022 | WO |
| WO2022272131 | Dec 2022 | WO |
| WO2023278725 | Jan 2023 | WO |
| WO2024137843 | Jun 2024 | WO |
| Entry |
|---|
| International Search Report and Written Opinion received for International Application No. PCT/US22/35764, filed Jun. 30, 2022; Applicant: Shifamed Holdings, LLC; dated Sep. 19, 2022; 10 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US22/34027, filed Jun. 17, 2022; Applicant: Shifamed Holdings, LLC; dated Oct. 25, 2022; 8 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US22/34995, filed Jun. 24, 2022; Applicant: Shifamed Holdings, LLC; dated Nov. 18, 2022; 17 pages. |
| Perk et al., “Catheter-based left atrial appendage occlusion procedure: role of echocardiography,” published on behalf of the European Society of Cardiology, Sep. 8, 2011, 7 pages. |
| Collado et al., “Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation,” Journal of the American Heart Association, Jun. 2021, 18 pages. |
| Jodi Perkins, “Corvia Medical and physiQ Partner in Global Phase 3 Heart Failure Clinical Trial to Leverage Novel Digital Endpoints,” Press Release, 2019 Copyright, Medical Alley Association, 3 pages. |
| Lehner et al., “The Creation of an Interatrial Right-To-Left Shunt in Patients with Severe, Irreversible Pulmonary Hypertension: Rationale, Devices, Outcomes,” Current Cardiology Reports (2019) 21: 31, https://doi.org/10.1007/s11886-019-1118-8; 9 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US19/69106 filed Dec. 31, 2019; Applicant: Shifamed Holdings, LLC; dated Mar. 23, 2020; 10 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US20/49996 filed Sep. 9, 2020; Applicant: Shifamed Holdings, LLC; dated Feb. 17, 2021; 16 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US20/063360 filed Dec. 4, 2020; Applicant: Shifamed Holdings, LLC; dated Apr. 5, 2021; 13 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US20/64529 filed Dec. 11, 2020; Applicant: Shifamed Holdings, LLC; dated Apr. 8, 2021; 12 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US19/68354, filed Dec. 23, 2019; Applicant: Shifamed Holdings, LLC; dated Mar. 17, 2020; 11 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US21/16932, filed Feb. 5, 2021; Applicant: Shifamed Holdings, LLC; dated Jun. 3, 2021; 11 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US21/14433, filed Jan. 21, 2021; Applicant: Shifamed Holdings, LLC; dated May 14, 2021; 16 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US21/14428, filed Jan. 21, 2021; Applicant: Shifamed Holdings, LLC; dated Jun. 8, 2021; 17 pages. |
| Ando et al., “Left ventricular decompression through a patent foramen ovale in a patient with hypertrophic cardiomyopathy: a case report,” Cardiovascular Ultrasound volume, Article No. 2 (2004). |
| Braunwald, Heart Disease, Chapter 6, 2015, p. 186. |
| Bridges et al., “The Society of Thoracic Surgeons practice guideline series: transmyocardial laser revascularization,” The Annals of Thoracic Surgery, vol. 77, Issue 4, Apr. 2004, pp. 1494-1502. |
| Bristow et al., “Improvement in cardiac myocyte function by biological effects of medical therapy: A new concept in the treatment of heart failure,” European Heart Journal, vol. 16, Issue suppl. F, Jul. 1995, pp. 20-31. |
| Case et al., “Relief of High Left-Atrial Pressure in Left-Ventricular Failure,” Lancet, Oct. 17, 1964, pp. 841-842. |
| Coats et al., “Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function,” Circulation, 1992;85:2119-2131. |
| Davies et al., “Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure,” Circulation, (1995), 92:2540-2549, Circulation, (1995), 92:2540-2549. |
| Ennezat et al., “An unusual case of low-flow, low gradient severe aortic stenosis: Left-to- right shunt due to atrial septal defect,” Cardiology, (2009), 113(2):146-148. |
| Ewert et al., “Masked Left Ventricular Restriction in Elderly Patients with Atrial Septal Defects: A Contraindication for Closure,” Catheterization and Cardiovascular Interventions, 52: 177-180, 2001. |
| Ewert et al., “Acute left heart failure after interventional occlusion of an atrial septal defect,” Z. Kardiol., Catheterization and Cardiovascular Interventions, Z. Kardiol., (May 2001), 90(5):362-366. |
| Geiran et al., “Changes in cardiac dynamics by opening an interventricular shunt in dogs,” J. Surg. Res., (Jan. 1990), 48(1):6-12. |
| Gelernter-Yaniv et al., “Transcatheter closure of left-to-right interatrial shunts to resolve hypoxemia,” Congenit. Heart Dis., (Jan. 2008), 31(1):47-53. |
| Gewillig et al., “Creation with a stent of an unrestrictive lasting atrial communication,” Cardio. Young, (2002), 12(4):404-407. |
| Khositseth et al., “Transcatheter Amplatzer Device Closure of Atrial Septal Defect and Patent Foramen Ovale in Patients With Presumed Paradoxical Embolism,” Mayo Clinic Proc., 79:35-41 (2004). |
| Kramer et al., “Controlled study of captopril in chronic heart failure: A rest and exercise hemodynamic study,” Circulation, (1983), 67(4):807-816. |
| Lai et al., “Bidirectional shunt through a residual atrial septal defect after percutaneous transvenous mitral commissurotomy,” Cardiology, (1993), 83(3):205-207. |
| Lemmer et al., “Surgical implications of atrial septal defect complicating aortic balloon valvuloplasty,” Ann. thorac. Surg., (Aug. 1989), 48(2):295-297. |
| Park et al., “Blade atrial septostomy: collaborative study,” Circulation, 66(2):258-266 (1982). |
| Roven et al., “Effect of Compromising Right Ventricular Function in Left Ventricular Failure by Means of Interatrial and Other Shunts,” American Journal Cardiology, 24:209-219 (1969). |
| Salehian et al., “Improvements in Cardiac Form and Function After Transcatheter Closure of Secundum Atrial Septal Defects,” Journal of the American College of Cardiology, 45(4):499-504 (2005). |
| Schmitto et al., “Chronic heart failure induced by multiple sequential coronary microembolization in sheep,” The International Journal of Artificial Organs, 31(4):348-353 (2008). |
| Schubert et al., “Left ventricular conditioning in the elderly patient to prevent congestive heart failure after transcatheter closure of the atrial septal defect,” Catheter Cardiovasc. Interv., (2005), 64(3):333-337. |
| Stormer et al., “Comparative study of in vitro flow characteristics between a human aortic valve and a designed aortic and six corresponding types of prosthetic heart valves,” European Surgical Research, (1976), 8(2):117-131. |
| Stumper et al., “Modified technique of stent fenestration of the atrial septum, Heart,” (2003), 89:1227-1230. |
| Trainor et al., “Comparative Pathology of an Implantable Left Atrial Pressure Sensor,” ASAIO Journal, Clinical Cardiovascular/Cardiopulmonary Bypass, 59(5):486-92 (2013). |
| Zhou et al., “Unidirectional valve patch for repair of cardiac septal defects with pulmonary hypertension,” Annals of Thoracic Surgeons, 60: 1245-1249, 1995. |
| International Search Report and Written Opinion received for International Application No. PCT/US20/12059, filed Jan. 2, 2020; Applicant: Shifamed Holdings, LLC; dated Jun. 5, 2020; 12 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US20/25509, filed Mar. 27, 2020; Applicant: Shifamed Holdings, LLC; dated Jun. 25, 2020; 9 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US20/26738, filed Apr. 3, 2020; Applicant: Shifamed Holdings, LLC; dated Jun. 30, 2020; 8 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US21/28931, filed Apr. 23, 2021; Applicant: Shifamed Holdings, LLC; dated Sep. 24, 2021; 20 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US21/27747, filed Apr. 16, 2021; Applicant: Shifamed Holdings, LLC; dated Oct. 1, 2021; 16 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US21/55191, filed Oct. 15, 2021; Applicant: Shifamed Holdings, LLC; dated Mar. 1, 2022; 12 pages. |
| Anomet Products “Conductive Nitinol Wire” Aug. 15, 2020, Retrieved from website <URL: https://helpx.adobe.com/acrobat/using/allow-or-block-links-internet.html?mv=product&mv2=acrobat>, 4 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US21/58996, filed Nov. 11, 2021; Applicant: Shifamed Holdings, LLC; dated Feb. 7, 2022; 18 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US22/19374, filed Mar. 8, 2022; Applicant: Shifamed Holdings, LLC; dated Jun. 24, 2022; 11 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US21/53836, filed Oct. 6, 2021; Applicant: Shifamed Holdings, LLC; dated Jan. 25, 2022; 20 pages. |
| International Search Report and Written Opinion received for International Application No. PCT/US21/47573, filed Aug. 25, 2021; Applicant: Shifamed Holdings, LLC; dated Feb. 3, 2022; 15 pages. |
| Kocaturk, O. et al., “Whole shaft visibility and mechanical performance for active MR catheters using copper-nitinol braided polymer tubes,” Journal of Cardiovascular Magnetic Resonance. Aug. 12, 2009, vol. 11, No. 29, p. 9, col. 1, In 5-6. |
| Hossain, M. et al. “In situ preparation of graphene-ZnO composites for enhanced graphite exfoliation and graphene-nylon-6 composite films,” Journal of Applied Polymer Science, Dec. 5, 2016, vol. 134, No. 27, p. 8, In 15-16. |
| http://www.collinsdictionary.com/dictionary/english/actuator, actuator definition and meaning, Accessed Oct. 18, 2023, 3 pages. |
| https://www.ahdictionary.com/word/search.html?q=actuator, American Heritage Dictionary Entry: actuator, Accessed Oct. 18, 2023, 1 page. |
| https://www.dictionary.com/browse/Actuator, Actuator definition & Meaning, Dictionary.com Accessed Oct. 18, 2023, 1 page. |
| Extended European Search Report received for Application No. 20896031.0, Applicant: Shifamed Holdings, LLC; Date of Mailing: Dec. 7, 2023; 11 pages. |
| Huang et al., “Shape Memory Materials,” Science Direct, Materials Today, vol. 13, Sep. 1, 2010, 15 pages. |
| Retrieved from the Internet: URL:https://www.sciencedirect.com/science.article/pii/S1369702110701280#bib1, retrieved on Jan. 22, 2024, 1 page. |
| Extended European Search Report received for Application No. 20896031.0, Applicant: Shifamed Holdings, LLC; Date of Mailing: Apr. 3, 2024; 6 pages. |
| English translation of Japanese Office Action received for JP 2022-515509, Applicant: Shefamed Holdings, Inc., mailed on May 30, 2024, 8 pages, |
| Extended European Search Report received for Application No. 20896031.0, Applicant: Shifamed Holdings, LLC; Date of Mailing: Jul. 4, 2024; 11 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20210085935 A1 | Mar 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62897943 | Sep 2019 | US | |
| 62907696 | Sep 2019 | US | |
| 63003594 | Apr 2020 | US | |
| 62907700 | Sep 2019 | US | |
| 62929608 | Nov 2019 | US | |
| 62907698 | Sep 2019 | US | |
| 62959792 | Jan 2020 | US | |
| 62976665 | Feb 2020 | US | |
| 63003632 | Apr 2020 | US | |
| 62977933 | Feb 2020 | US | |
| 62994010 | Mar 2020 | US | |
| 63002050 | Mar 2020 | US |
